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INTRODUCTION 
Juvenile nasopharyngeal angiofibroma (JNA) is a fibrous and vascular tumour that 
commonly involves the nasopharynx.1 It accounts for < 0.5% of head and neck tumours 
and primarily affects male adolescents.2 It is a nonencapsulated, submucosal spreading 
tumour which is locally destructive. Originating from the superior posterior margin of the 
sphenopalatine foramen, progression of the tumour is often slow with extension into the 
pterygopalatine fossa, the paranasal sinus or infratemporal fossa.3 
 
Recurrent severe epistaxis accompanied by progressive nasal obstruction is the classical 
symptom of juvenile angiofibromas at the time of presentation. Other signs and 
symptoms of tumour growth and extension may include swelling of the cheek, trismus, 
hearing loss, anosmia and a nasal intonation or plumy quality of the voice. More 
extensive tumour growth with invasion of orbit and cavernous sinus can cause proptosis, 
diplopia, visual loss, facial pain and headache.4  
 
For tumour evaluation towards staging and planning for treatment, contrast computed 
tomography (CT) and magnetic resonance imaging (MRI) reliably assess tumour extent. 
Preoperative arteriography is helpful to evaluate feeding vessels and allows embolization 
of these highly vascular lesions.5  
 
The mainstay treatment of JNA is surgery, although radiotherapy, hormone therapy, 
cryotherapy, electrocoagulation, and chemotherapy have all been described in the 
literature. Most authors prefer external surgical approaches and reserve radiation for 
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unresectable intracranial tumours or as post-operative adjunctive therapy when residual 
tumour has to be left behind.6  
 
Intraoperative bleeding is one of the major concerns during operation. In an attempt to 
reduce intraoperative bleeding to a minimum, transcatheter embolization of JNA is often 
undertaken preoperatively.7 
 
Recurrence is by far the most common complication encountered and may develop in up 
to 40 percent of these patients.8 
 
This study was undertaken in a tertiary care hospital in South India, to describe the 
clinical profile of patients who were diagnosed to have juvenile nasopharyngeal 
angiofibroma and to assess the factors associated with its recurrence. 
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AIMS OF THE STUDY 
 
1. To describe the clinical profile of patients diagnosed to juvenile nasopharyngeal 
angiofibroma. 
 
 
2. To determine the rate of recurrence and to analyze factors involved in recurrence. 
 
 
3. To analyze factors affecting intra-operative blood loss. 
 
 
 
 
 
 
 
 
 
 
 
 
 4
OBJECTIVES OF THE STUDY 
 
 
(a) To describe the spectrum, frequency and duration of symptoms in patients 
diagnosed to have juvenile nasopharyngeal angiofibroma. 
 
(b) To evaluate the extent of tumour involvement at presentation on imaging. 
 
(c) To determine the relationship between staging of tumour and 
i. Age 
ii. Duration of symptoms prior to presentation 
 
(d) To evaluate factors that predicts recurrence of disease. 
 
(e) To describe the clinical profile of patients who present with recurrence of tumour 
after primary surgical treatment. 
 
(f) To evaluate the extent of tumour involvement at the time of recurrence by 
imaging. 
 
(g) To compare the clinical profile of primary and secondary (recurrent) cases. 
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PRESENT KNOWLEDGE AND REVIEW OF LITERATURE 
Introduction and historical aspects 
Juvenile nasopharyngeal angiofibroma (JNA) is a fibrous and vascular tumour that 
commonly involves the nasopharynx.1 Juvenile nasopharyngeal angiofibroma (JNA) 
accounts for < 0.5% of head and neck tumours and primarily affects male adolescents.1 It 
is a nonencapsulated, submucosal spreading tumour which is locally destructive. 
Originating within the superior posterior margin of the sphenopalatine foramen, 
progression of the tumour is often slow, uneventful, and undetected until the tumour has 
extended into the pterygopalatine fossa or the paranasal sinus, or with the occurrence of 
atypical symptoms.1 Nasopharyngeal angiofibromas have been identified since ancient 
times and Hippocrates (470 – 471 BC) removed the “hard nasal polyp” through a 
midline, nasal-splitting incision. The first successful surgical treatment (total 
maxillectomy) is credited to Liston at the University College Hospital in London in 1841. 
The term “nasopharyngeal fibroma” was first coined by Chauveau.9 Friedberg suggested 
the name ‘angiofibroma’ in 1940.1  
 
Site of origin and spread of tumour 
The point of tumour origin is important in that its location helps predicts tumour growth 
and influences the surgical approach and tumour excision. A number of theories have 
been propounded over the years to explain the origin of angiofibromas and although one 
or two are seemingly plausible, none is entirely convincing. Ringertz (1938) suggested 
that the tumour arouse from the periosteum of the nasopharyngeal vault, while Som and 
Neffson (1940) believed that inequalities in the growth of the bones forming the skull 
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base resulting in hypertrophy of the underlying periosteum in response to a hormonal 
influence. Bensch and Ewing (1941) thought that the tumour probably arose from 
embryonic fibrocartilage between the basiocciput and basisphenoid. Brunner (1942) 
believed an origin from the conjoined pharyngobasilar and buccopharyngeal fascia. 
Osborn (1959) considered two alternatives, namely the possibility that the swellings were 
either hamartomas, or residues of fetal erectile tissue which were subject to hormonal 
influences. Girgis and Fahmy (1973) noted cell nests of undifferentiated epithelioid cells 
or ‘zellballen’ at the growing edge of angiofibromas, an appearance which they likened to 
that of paragangliomas. They also commented on the existence of paragangliomatous 
tissue around the terminal part of the maxillary artery in the pterygopalatine fossa of 
stillborn infants.10 The occurrence of these rare tumours almost exclusively in adolescent 
males supports the hypothesis that an alteration of the pituitary androgen-estrogen axis 
contributes to the pathogenesis of JNA.11 Exhaustive studies of the pituitary- gonadal axis 
in these patients, however, have failed to identify any endocrinologic abnormality. The 
most widely accepted theory of origin of JNA is that the tumour is derived from 
embryologic chondrocartilage during the development of the cranial bones.11 This tumour 
is said to originate form the superior margin of the sphenopalatine foramen and has a 
tendency to grow and extend along the natural foramina and fissures associated with its 
site of origin. From its origin, the tumour can grow unimpeded into the nasopharynx and 
nasal cavity, invade maxillary, ethmoid, or sphenoid sinuses by bone destruction, and 
spread laterally into the pterygopalatine fossa. From here, the tumour can erode the 
pterygoid plates leading into the infratemporal fossa or grow through the inferior orbital 
fissure into the orbit. From the infratemporal fossa, superior extension of tumour would 
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involve the pterygoid process and the foramina rotundum, ovale, and lacerum to involve 
the middle cranial fossa. From the middle cranial fossa, the tumour can invade the 
parasellar region, usually remaining extradural and lateral to sphenoid sinus. There are 
two patterns of intracranial extension. The first is through destruction of skull base at the 
attachment of pterygoid process, lateral to the internal carotid artery. The second is 
through the sphenoid sinus and into the region of the cavernous sinus.12 
 
Pathogenesis 
As this tumour is almost exclusively found in adolescent boys, there has always been 
much speculation and indirect evidence that sex-hormone receptors play some part in its 
development. Recent immunocytochemical techniques have been used to show that 
androgen receptors are present in at least 75 percent of tumours, these receptors being 
present in both vascular and stromal elements. A much smaller proportion of tumours 
also have some progesterone receptors. In contrast, oestrogen receptors have not been 
demonstrated. Other factors also play their part in the development of this tumour. The 
angiogenic growth factor (Vascular Endothelial Growth Factor (VEGF)) has been found 
localized on both endothelial and stromal cells, perhaps indicating that both cell types 
play a role in tumour development. Vessel density and both the expression and 
localization of VEGF correlate with the proliferative marker Ki67. However, neither the 
proliferative index nor VEGF expression seems to bear any relation whatsoever to the 
stage of tumour at time of presentation; in other words, its degree of aggressiveness. Over 
expression of insulin-like growth factor II (IGF II) has also been found in a large number 
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of juvenile angiofibromas. It is thought the over-expression of IGF II might be associated 
with a tendency to recurrence and poorer prognosis.4  
 
Symptoms and signs 
Recurrent severe epistaxis accompanied by progressive nasal obstruction is the classical 
symptoms of juvenile angiofibromas at the time of presentation. Epistaxis may vary in 
severity from the occasional show to an alarming and sometimes a life-threatening event. 
Chronic anaemia is thus a common feature of the established condition. Bleeding which 
occurs prior to surgery is entirely spontaneous and usually unconnected with trauma. 
Nasal obstruction is often complete such that stasis of secretions and sepsis are virtually 
inevitable, followed by hyposmia and anosmia. The voice acquires a nasal intonation and, 
if the swelling is large enough to force the soft palate down, there may be an added 
plummy quality to it. Blockage of the eustachian tube is not uncommon in such a 
situation and leads to deafness and Otalgia.10 
 
Anterior rhinoscopy is likely to confirm the presence of abundant mucopurulent 
secretions together with bowing of the nasal septum to the uninvolved side. Posterior 
rhinoscopy in the cooperative relaxed patient usually displays a pink or red mass filling 
the nasopharynx, but the sheer bulk of the lesion rarely allows the examiner to determine 
its precise site of origin. Gross physical signs are evident when extensive disease has 
involved the nose and infratemporal fossa. The nasal bones are often splayed out and 
there may be obvious swelling in the temple and cheek. Intraoral palpation in the interval 
between the ascending ramus of the mandible and the side of maxilla may also reveal a 
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fullness caused by a tumour which has crept around the back of antrum. Impaction of 
bulky disease in the infratemporal fossa results in extreme signs such as trismus and 
bulging of the parotid gland, while proptosis is a definite sign that the orbital fissures 
have been penetrated. The classical frog face is the ultimate picture of massive escape of 
disease. Headache is not uncommon in patients with large tumours and is often 
attributable to chronic sinusitis. Falling vision indicates tenting of the optic nerve over a 
substantial extra nasopharyngeal extension of the tumour.10 
 
These tumours do not grow fast and so many months or even years may pass before it 
occurs to the patient or their parents that there is anything seriously amiss. In most, there 
is a delay of at least six or seven months between the onset of symptoms and 
presentation.4 
 
Histopathology 
The gross appearance of the neoplasm is of a lobulated, pink to purplish mass with a 
smooth surface. They are covered by intact mucosa on their nasopharyngeal surface 
(unless previously biopsied). The cut surface has a fibrous appearance, often with blood 
vessels seen at the base of resection. Histologically, the tumour consists of two main 
cellular components, a fibrous stroma consisting of spindle or stellate-shaped cells in a 
dense collagen matrix, and a rich network of irregularly shaped blood vessels. The 
vessels vary from small endothelial-lined capillaries to large venous channels. A 
characteristic feature of these channels is a distinct lack of smooth muscle and elastic 
fibers found in normal blood vessels, which contributes to the tumour’s hemorrhagic 
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propensity after even minimal manipulation. The stromal cells appear to be of fibroblastic 
and myofibroblastic origin.13  
 
Diagnosis 
During initial evaluation, contrast computed tomography (CT) and magnetic resonance 
imaging (MRI) reliably assess tumour extent. CT diagnosis is based on two constant 
features that include (1) mass in nose and pterygopalatine fossa and (2) erosion of bone 
behind the sphenopalatine foramen at the root of the pterygoid plate.1 Areas inaccessible 
to clinical examination, such as posterior part of nasal cavity, the sphenoid and ethmoid 
sinuses, the pterygopalatine fossa, the middle cranial fossa and sometimes the 
nasopharynx, are delineated well on axial CT cuts. Of particular help is the ability of CT 
to reveal erosion of the sphenoidal sinus and the skull base - both potential routes of 
intracranial extension which may be a source of recurrence if left unrecognized. CT 
demonstrates well widening of the pterygopalatine fossa - a sign strongly suggestive of 
JNA. With expansion of the tumour, anterior bowing of the posterior antral wall may be 
seen on plain radiographs and CT. This is the ‘antral sign’ described by Holman and 
Miller in 1965. The tumour’s attenuation coefficient of 35 Hounsefield numbers enables 
orbital and intracranial involvement to be easily detected since, in both these areas, the 
surrounding tissues have smaller attenuation coefficients. Hence preoperative CT 
scanning is a vital adjunct in deciding on the approach, particularly in recurrent cases 
where previous surgical attempts and scarring invariably alter the true picture.14  
Magnetic resonance imaging with gadolinium enhancement allows the surgeon to more 
accurately stage the lesion and plan for surgical approach. It offers additional information 
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about possible intracranial and cavernous sinus extension.11 It provides multiplanar 
imaging; improved definition at the cribriform plate and cavernous sinus, superior 
differentiation of the tumour from inflamed mucosa and fluid in sinuses, and avoidance 
of diagnostic radiation in patients who require serial follow up.15 The main advantage of 
MRI, however, lies in post-treatment surveillance of residual tumours or recurrent 
disease.13  Preoperative arteriography is helpful for the evaluation of feeding vessels and 
allows embolization of these highly vascular lesions.5 
 
Biopsy is rarely required to establish the diagnosis and should be avoided because of the 
risk of hemorrhage.15 Despite classic radiographic findings, there is no absolute 
radiological sign of nasopharyngeal angiofibroma. If the tumour appears atypical or if 
patient’s clinical history is unusual, then biopsy should be considered before tumour 
resection. This should be performed in the operation theatre as significant hemorrhage 
may require anterior and post nasal packing or cauterization and is best handled in a 
controlled environment. Fibrous dysplasia, lymphoepithelioma, and rhabdomyosarcoma 
have been known to mimic nasopharyngeal angiofibroma.11  
 
Staging system for JNA 
While there is usually a linear relationship between tumour size and extranasopharyngeal 
extension, size is not consistently measurable. As in malignant neoplasms of the 
nasopharynx, tumour staging is based on sites of involvement. Staging is important for 
individual evaluation as well as inter institutional treatment comparisons. Several staging 
system are proposed. 
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Chandler et al (1984)16 
Stage I Tumour  confined to the nasopharyngeal vault 
Stage II Tumour extending into nasal cavity and/or sphenoid sinus 
Stage III Tumour extending into antrum, ethmoid sinus, pterygomaxillary fossa, infratemporal fossa, orbit and or cheek 
Stage IV Intracranial tumour 
 
Sessions et al (1981)17 
Stage I A Tumour limited to posterior nares/or nasopharyngeal vault 
Stage I B Tumour involving posterior nares and/or nasopharyngeal vault with involvement of at least 1 paranasal sinus 
Stage II A Minimal lateral extension into pterygomaxillary fossa 
Stage II B Full occupation of pterygomaxillary fossa with or without superior erosion of orbital bones 
Stage II C Infratemporal fossa with or without cheek 
Stage III Intracranial extension 
 
Radkowski (1996)11 
Stage I A Tumour limited to nose and/or nasopharyngeal vault 
Stage I B Tumour involving nose and/or nasopharyngeal vault with involvement of at least 1 paranasal sinus 
Stage II A Minimal lateral extension into pterygomaxillary fossa 
Stage II B 
Full occupation of pterygomaxillary fossa with or without superior erosion of orbital 
bones 
 
Stage II C Infratemporal fossa or posterior to pterygoid plates 
Stage III A Erosion of base of skull (middle cranial fossa/base of pterygoids) – minimal intracranial extension 
Stage III B Extensive intracranial extension with or without extension into the cavernous sinus 
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Classification according to Fisch10 
 
Stage I Tumours limited to nasal cavity, nasopharynx with no bony destruction  
Stage II Tumours invading pterygomaxillary fossa, paranasal sinuses with bony destruction 
Stage III Tumours invading infratemporal fossa, orbit and/or parasellar region remaining lateral to cavernous sinus 
Stage IV Tumours invading cavernous sinus, optic chiasmal region, and/or pituitary fossa 
 
Andrews staging of angiofibroma18 
Stage I Tumour limited to the nasal cavity and nasopharynx 
Stage II Extensions into pterygopalatine fossa, maxillary, sphenoid, ethmoid sinuses 
Stage IIIa Extensions into orbit or infratemporal fossa without intracranial extensions
Stage IIIb Stage IIIa with small extradural intracranial (parasellar) involvement 
Stage IVa Large extradural intracranial or intradural extensions 
Stage IVb Involvement of the cavernous sinus, pituitary, or optic chiasm 
 
Chandler’s staging system was based on a system proposed for nasopharyngeal cancer. 
JNA, however, is a benign lesion with a predictable growth pattern that differentiates it 
from malignant nasopharyngeal tumours. In Chandler’s staging system stage III includes 
all extranasopharyngeal sites except sphenoid sinus and intracranial extension. The 
inclusion of multiple sites with variable resectability into a single stage limits the clinical 
usefulness of the system.11  
 
Sessions system of classification more accurately reflects the clinical behavior of JNA.17 
In 1993, Radkowski further modified Sessions classification to include posterior 
extension to pterygoid plates and the extent of skull base erosion.11 
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Treatment 
The mainstay treatment of JNA is surgery, although radiotherapy, hormone therapy, 
cryotherapy, electrocoagulation, and chemotherapy have all been described in the 
literature. Most authors prefer external surgical approaches and reserve radiation for 
unresectable intracranial tumours or as post-operative adjunctive therapy when residual 
tumour has to be left behind.6 
 
Until relatively recently, most small tumours were resected either through a transpalatal 
approach, lateral rhinotomy or mid-facial degloving approach. Open approaches can be 
used for tumours of all stages and certainly were only option before the application of 
endonasal endoscopic techniques became more widespread.19 
 
The treatment should take into account the following factors: 1) tumour growth in 
prepubescent boys may give rise to significant morbidity, 2) a wide approach to the skull 
base may also result in significant morbidity, and 3) JNA has an unusual natural history 
in which tumour remnants may become involuted or stabilize with maturity.19 
.  
Surgical approaches for JNA 
Various surgical approaches are described for excision of JNA including endoscopic 
transnasal, transpalatal, medial maxillectomy, facial translocation and infratemporal fossa 
approaches with or without craniotomy.15 From a practical standpoint, the choice of 
surgical approach is based heavily on the surgeon’s experience and training. However, 
several basic concepts are critical: adequate exposure of the tumour, ability to control 
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bleeding, no postoperative facial scar or deformity, and no interference with the growth 
of the facial skeleton. Exposure of the tumour and hemostasis are a high priority and 
often are cited as the justification for aggressive and potentially deforming transfacial 
approaches. Avoidance of scars, deformity, or interference with facial growth has gained 
greater importance as treatment philosophies that emphasize quality of life have evolved, 
with surgeons developing techniques that minimize functional as well as cosmetic 
deficits.20 
 
Transpalatal 
The transpalatal approach was formerly used for removal of nasopharyngeal 
angiofibromas, but it is not as popular as it once was.21 It is suited for tumour limited to 
the nasopharynx, nasal cavity and sphenoid sinus because lateral exposure is limited.13 
 
The best incision is one that is placed just inside the upper alveolus to provide a large 
palatal flap. The incision is made down to the bone with a knife and the soft tissue is 
elevated from the bone backwards to the posterior edge of the hard palate. The exposure 
is increased by extending the incision backwards into the soft palate and if necessary 
dividing the greater palatine vessel on one side. The bony hard palate is then removed as 
necessary, using a cutting burr and bone-nibbler forceps. It is important that there is 
always bone underneath the incision line or else an oronasal fistula occurs. Since removal 
of bony hard palate is always necessary in this approach, it is important to make the 
incision as far forward as possible. A palatal fistula may results in as many as 40% of 
patients.21  
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Lateral Rhinotomy 
Lateral rhinotomy is the traditional and standard technique for tumour of nose and 
paranasal sinuses. The lateral rhinotomy incision is effective for the exposure of the 
nasopharynx, paranasal sinuses, and pterygopalatine fossa and the medial parts of the 
infratemporal fossa, as well as cavernous sinus. This external approach can allow optimal 
access with extensive tumours, yet with significant detriments because it may interfere 
with facial development or impose various dysfunctions.22  
 
The principle disadvantage of the approach is that it leaves a long facial scar. With 
careful incision and suturing, however the scar can largely be hidden in the natural 
creases and shadow area of the face.23 
 
Midfacial degloving 
Midfacial degloving operation was first published by Casson et al. and described by 
Howard and Lund. This approach provides good exposure to target area and excellent 
cosmoses by avoiding external incision.23 The exposure of the lower part of midface 
including the nose and maxillary sinus up to the orbit is excellent. The limitation of this 
approach is that it affords relatively poor access to orbit, the lateral aspect of maxilla, and 
the ethmoid sinus. Complication of this approach includes hematoma under the cheek 
flap and nasal vestibule stenosis.19 A study done by El-Banhawy el al, evaluated 15 
patients with type III (Fisch classification) primary JNA treated with endoscopic assisted 
midfacial degloving approach. Thirteen patients had complete tumour clearance with no 
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esidual or recurrence during the follow-up period. Recurrence was detected in 2 patients 
at 3 and 8 months post-operatively.6  
 
Extended osteoplastic maxillotomy 
The osteoplastic maxillotomy is a versatile new approach that can provide extensive 
exposure to the central skull base and infratemporal fossa and corresponding intracranial 
anatomy. Briefly, the maxillofacial skeleton is partially exposed via a Weber-Fergusson 
incision. Osteotomies in the maxilla and zygoma completely disengage the maxilla from 
the facial skeleton. The maxilla is mobilized on the skin and soft tissue of the ipsilateral 
cheek, maintaining its vascularity. Medial positioning of the anterior osteotomy through 
the face of the maxilla determines the extent of exposure to the nasopharynx. The lateral 
osteotomy at the malar eminence determines the extent of exposure to the infratemporal 
fossa. Concurrent use of temporal craniotomy provides corresponding access to the 
cranial cavity. Hearing and facial nerve are preserved. Form and function of maxilla are 
restored using miniplate fixation.24 
 
Infratemporal fossa approach 
The Fisch infratemporal fossa type C approach offers excellent skull base exposure for 
extradural tumours. With this procedure, a postauricular approach is used to perform a 
mastoidectomy and subtotal petrosectomy. The mandibular branch of the trigeminal 
nerve is sectioned, and after tumour removal the middle ear structures are removed, 
middle ear obliterated and Eustachian tube closed. This approach allows the patient to 
avoid facial incisions and a craniotomy; but it results in a permanent ipsilateral 
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conductive hearing loss and chin numbness.25 Benefits of this approach includes: (1) 
direct visualization of the internal carotid artery while removing tumour; (2) a very short 
working distance; (3) ideal illumination, magnification, and binocular vision with use of 
the operating microscope; and (4) the potential exposure of the cavernous sinus through 
limited extradural temporal lobe elevation.26 
 
When the angiofibroma is limited to either the infratemporal or pterygopalatine fossa and 
is not encroaching upon the internal carotid artery, the infratemporal fossa type D1 and 
D2 approaches may be used. As they avoid dissection through the middle ear, conductive 
hearing is preserved. These approaches are used to remove tumours involving the anterior 
cranial fossa and orbital apex and are typically carried out through either an extended 
preauricular (D1) or hemicoronal (D2) skin incision. The principle benefits of this 
approach include; (1) direct tumour access within the fossae; (2) no conductive hearing 
deficit: (3) avoidance of visible facial scars: (4) maintenance of normal facial contour: 
and (5) the potential to be converted to type C approach if necessary. The deficits 
associated with the type D approaches are very limited.26  
 
Endoscopic 
Endoscopic surgery in the nasal cavity and paranasal sinuses initially was used to treat 
non-neoplastic disease (polyposis, acute and chronic sinusitis, etc). As the skills of 
endoscopic surgeons improved, these techniques were adopted to excise benign 
neoplasms and more recently to remove locally confined malignancies. Tumours that 
involve the ethmoid, maxillary or sphenoid sinus, the sphenopalatine foramen, 
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nasopharynx, pterygomaxillary fossa and have limited infratemporal fossa involvement 
are amenable to endoscopic resection. Angiofibroma that involve the orbit or middle 
cranial fossa are not ideal for endoscopic excision and require more extensive surgery 
involving an intracranial - extracranial approach.5 New advancements with endoscopic 
techniques today permit a minimally invasive resection of the entire tumour mass with 
minimal blood loss or morphological disturbance. Endoscopic procedures combined with 
computer-assisted systems avert complications resulting from lengthy radiation 
treatments as well.22 A study in 20055 revealed relatively less blood loss with endoscopic 
approach compared to traditional lateral rhinotomy approach. The relatively low level of 
blood loss may be due to meticulous nature of dissection. Even small amount of bleeding 
limit the surgeon’s endoscopic view and thus careful attention to hemostasis is essential 
for a successful outcome. In addition, much of the blood loss in traditional approaches 
results from the incisions and osteotomies of surgical access. Gilles Roger et al27 
evaluated 20 patients operated exclusively with endoscopic surgical approach. 
Endoscopic surgery was associated with a shorter duration of hospitalization with most 
patients discharged within 48 hours after surgery. In addition, endoscopic surgery avoids 
the complications specifically related to different approaches with open surgery 
(Epiphora, dysesthesia, trismus, pain, and possible effects on facial growth). 
 
Lefort I osteotomy 
This technique involves creating a transverse facial osteotomy along the lines of the 
classic Le Fort I fracture and inferiorly displacing the palate to expose nasopharynx, 
clivus, and posteriorly the sphenoid sinus. Among the advantageous of this option over 
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the other approaches to this area are the ease, rapidity, and safety with which it can be 
performed and its excellent cosmetic and functional results.23 Occasionally, there can be 
troublesome bleeding from a torn maxillary artery which may be difficult to deal with via 
this approach. While it gives adequate access, it may need intramaxillary fixation 
postoperatively and the osteotomy is contraindicated under the age of 12 years because of 
the risk of the canine dentition. This degree of tissue damage is not really acceptable for 
angiofibroma.21  
 
Role of radiation in JNA 
Although radiation has been reported as an effective means of therapy for JNA, potential 
long term complications have dissuaded some from pursuing this modality of treatment. 
Secondary malignancies of the head and neck signify one of the most feared adverse 
sequelae of radiation exposure. Multiple papers have also reported deleterious effects on 
the visual system. However, it should be recognized that in many of these cases orbital 
involvement might have prevented proper eye shielding. The greater precision achieved 
with the recent development of three-dimensional conformal planning and intensity-
modulation radiation therapy should succeed in more effectively shielding the lens from 
the irradiated field, even in context of significant orbital involvement.28 
 
There has also been concern that radiation may affect growth centers in the face leading 
to abnormal development of the craniofacial skeleton, especially in the maturing 
adolescent. In view of the potential long-term complications of radiation therapy, many 
institutions still consider surgery to be the treatment of choice even for patients with 
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intracranial extension. Both extracranial and combined neurosurgical/otolaryngologic 
techniques have been described in the literature with varying degree of success. However, 
irrespective of whether extracranial or intracranial approaches are used, serious 
complications have been reported to ensue from surgical intervention. Life threatening 
hemorrhage, optic neurovascular bundle injury, cranial nerve damage, meningitis, and 
motor nerve deficits have all been reported.28  
 
Preoperative chemotherapy 
Oestrogens have been reported to induce shrinkage in some cases but their effect is 
variable and not without complication. At the very first, oestrogen therapy delays surgery 
and the secondary feminizing effects are certainly unwanted by an adolescent boy. In a 
small series of patients given the nonsteroidal androgen receptor blocker, flutamide, 
tumour shrinkage of up to 44 percent was reported by Gates et al.29 Side effects of 
flutamide include nausea, breast tenderness and gynaecomastia. These effects were 
temporary and disappeared completely at the end of therapy. It appears that this drug 
might have a role in the preoperative preparation of patients with very advanced tumours, 
certainly those with intracranial extension. Unfortunately, in a pilot study of seven 
patients with stage IV disease the mean shrinkage achieved was 7.5% and this was 
considered to be insignificant.4  
 
Embolization 
As JNA is highly vascular, intraoperative bleeding is one of the major concerns during 
surgery. In an attempt to reduce intraoperative bleeding to a minimum, transcatheter 
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embolization of JNA is often undertaken preoperatively. The vascular supply of the JNA 
depends on the size and extension of the tumour. In the initial stages, when the tumour 
grows in the anterior nasopharynx and posterior portion of nasal cavity, there is a 
constant blood supply from the distal internal maxillary artery and its branches extending 
to the nasopharynx and nasal cavity (sphenopalatine and pterygopalatine arteries). As the 
tumour grows and involves more regions (sphenoid sinus, parapharyngeal spaces, etc.), 
other vessels, from both the internal and external carotid arteries, contribute to its 
vascular supply.2 The goal of preoperative endovascular embolization is to achieve 
tumour devascularization whilst preserving a normal vascular supply to the surrounding 
tissues. This may be accomplished by the selective obliteration of the intratumoural 
vascular net. Reduction in peroperative blood loss after embolization may facilitate 
exposure of the tumour and the anatomical identification of the important structures 
during surgery, increasing the chances of achieving a radical tumour removal.2 Severe 
complications like cerebral infarct and vision loss have been reported in the literature 
after tumour embolization with various techniques, which are generally secondary to 
dangerous collaterals from the internal maxillary artery to the intracranial/ intraorbital 
contents.30 
 
Recurrence 
Recurrence is commonly encountered following surgery and may develop in up to 40 
percent of these patients. Not surprisingly, recurrence is more likely in patients with 
advanced disease and in those treated by inexperienced surgeons.4  
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Factor predicting rate of recurrence 
(1) Age of presentation: Petruson et al2 described that patients who were young at 
diagnosis were more likely to have recurrence than a patient who was older when the 
tumour was diagnosed.  
(2) Anatomical factors: On the basis of review of preoperative CT and MRI, Lloyed et 
al.31 determined that 93% of recurrence occurred in patients with invasion of sphenoid 
dipole through pterygoid canal. A further study in 200132 evaluated 19 patients 
undergoing surgical resection of angiofibroma and meticulous exploration and drilling of 
basisphenoid bone. Follow up of this cohort revealed no recurrence in this group, 
provoking the conclusion that careful attention to basisphenoid and pterygoid canal could 
nearly eliminate all residual disease. Deeper extension along the cancellous bone of the 
sphenoid and the pterygoid palates increases the likelihood that tumour remnant may be 
left behind at the time of surgery. Careful attention to this area and drilling of the bone 
surrounding the pterygoid canal intraoperatively may reduce the chance of leaving a 
tumour remnant in this area. Recurrence is inextricably linked to intracranial extension. 
Most studies cite a 10-20% incidence of intracranial extension, with a rate of nearly 50% 
of recurrence in these patients. On the basis of high rate of recurrence with intracranial 
extension, a combined craniofacial approach in needed in these patients.5  
(3) Embolization: Some authors found that preoperative embolization reduced 
recurrences as well as intraoperative blood loss at primary surgery. McCombe et al. 
found that the strongest predictor of recurrence to be preoperative embolization, as 
embolization shrinks the tumour but makes complete excision more difficult, especially if 
there is deep invasion of the sphenoid.2  
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Treatment of recurrence 
The presence of persistent radiographic abnormalities does not necessary signify residual 
tumour. Only if the patient develops symptoms or if new radiographic abnormalities arise 
is it necessary to pursue further treatment.28 
Hemorrhagic risk 
The resection of angiofibroma is classically considered to be high risk surgery 
particularly with respect to hemorrhage that may require blood transfusion, which is not 
without morbidity. In addition, perioperative bleeding can significantly hinder the 
excision. 
 
The greater availability of procedures for autologous blood donation has allowed the use 
of heterogenous transfusions to be avoided. However, collecting autologous units can 
delay surgery by several weeks. Further this may be hindered by significant epistaxis.  
The risk of perioperative bleeding is greater at certain sites of dissection, for example, 
adjacent to the internal maxillary artery, the body of sphenoid sinus, and the roots of the 
pterygoids, the interpterygoid fossa as well as in the region of cavernous sinus.4 
 
Complications 
Postoperative complications varied and depended on the extent of surgery performed. A 
palatal fistula may result when the transpalatal route is used, especially if the incision is 
sited directly over the junction of hard and soft palate. Surgically induced infraorbital 
nerve sensory deficits are recognized as a potential complication of mid-facial degloving, 
as is nasal vestibular stenosis. Prolong nasal crusting is also common and this may well 
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develop into ozaena. With more extensive resections, ocular problems may be 
experienced including displacement of the globe caused by loss of bony support, 
ophthalmoplegia and visual loss.4 Other reported complications are postoperative 
hemorrhage, meningitis, cerebrospinal fluid leakage, dental malocclusion, rhinolalia 
aparta, lacrimal duct stenosis and secretory otitis media.7  
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MATERIALS AND METHODS 
 
Study Design: Non-concurrent prospective cohort study 
 
Study population: All patients with histological proven juvenile nasopharyngeal 
angiofibroma, who underwent either primary or secondary surgical treatment at our 
institution (Christian Medical College, Vellore) between 1998 and 2008 
 
Inclusion criteria: All patients with histologically proven JNA who underwent surgical 
treatment at our hospital over the specified period 
 
Exclusion criteria: Patients with a diagnosis of JNA who did not undergo surgical 
treatment. 
 
Informed Consent: Informed consent was obtained from all patients enrolled in the 
study. The consent form is attached as Appendix A. Institutional Research Board (IRB) 
approval was obtained from the institution for the conduct of the study.  
 
Operational Definitions: For the purposes of this study,  
1. Primary cases were defined as patients who were newly diagnosed to 
have juvenile nasopharyngeal angiofibroma and did not have any 
previous surgical intervention prior to presenting to our institution. 
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2. Patients with recurrence were defined as those who already had primary 
surgical treatment either in this institution or elsewhere and who 
manifested clinical symptoms or signs of recurrence. 
 
Methodology 
Step 1: Identification of patients 
a) A search of the database of hospital admissions with a diagnosis of JNA was 
performed by medical records to identify index cases (both primary and 
secondary cases as defined above) 
b) In addition a systematic search of the operation records of the ENT department 
during the period of interest (1998-2008) was done to identify any missed cases. 
c) New cases of JNA that were diagnosed in the department during the study period 
(2007-2008) were also included 
 
Step 2: Patient contact to collect and update data  
a) New patients recruited during 2007-2008 were approached either in the outpatient 
clinic or in the ward for willingness to participate in the study 
b) Patients who were already operated and who presented for follow up during 2007-
2008 were approached for willingness to be part of the study 
c) Other patients were contacted by mail and/or by telephone to request for either a 
review at the hospital if possible or to answer certain queries by phone or mail 
regarding symptoms of recurrence. Consent was obtained during this process. 
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Step 3: Data collection and abstraction 
a) Data was obtained from medical records and by patient evaluation during hospital 
visit 
b) Data was entered in the proforma (attached) 
c) Data included demographics, symptomatology, extent of tumour (determined by 
imaging), surgical approach, complications and symptoms of recurrence (if 
present) 
 
Step 4: Statistical aspects 
 a) Sample size calculation and rationale 
 
Sample size for this descriptive study was calculated using the formula 
 
    N = 4 PQ (Za + Zb) 2 / d2  
                             
                       Where 
   N is number of sample size 
 P is prevalence of recurrence of disease - 27 % (Herman et al19)  
Q is complement of prevalence = 73 
d is effective measure (difference between estimate and variation allowed) - 
20% 
Calculated sample size N = 77 for this study. 
b) Analysis 
 
Statistical analysis was based on the appropriate statistical tests of significance.  The χ2 
test and the Fisher’s exact test were used for categorized bivariate analysis. The Student’s 
t-test was used to compare the mean differences of the continuous variables. A P value of 
< 0.05 was considered as significant. 
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RESULTS 
This study was conducted over a period of 19-months (April 2007 to October 2008) in 
the ENT Department of the Christian Medical College & Hospital (CMCH), Vellore. 
Patients with histologically proven Juvenile Nasopharyngeal Angiofibroma (JNA), who 
underwent surgical treatment in our institution from 1998, were identified from the 
hospital records. These patients were contacted by post and/or telephone and requested to 
present to hospital for review. In addition, new patients diagnosed to have JNA, who 
underwent surgical treatment in our hospital during the mentioned study period and who 
consented to participate in the study were also recruited. 
 
A total of 63 patients who had undergone surgical treatment at CMCH were identified 
from the hospital records. An additional 15 patients were recruited during the study 
period. Thus, a total of 78 patients with histologically proven juvenile nasopharyngeal 
angiofibroma who underwent surgical treatment at our institution formed the study 
cohort. Of these, 59 patients were newly diagnosed patients who had no surgical 
intervention prior to presentation at our institution. The remaining 19 patients presented 
with recurrence having had surgical treatment elsewhere (Figure 1). The mean (SD) 
duration of follow up of the primary cohort was 16.95 (20.32) months. The mean (SD) 
duration of follow up of patients with secondary disease was 18.77 (23.79) months. 
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Figure 1: Distribution of patients in the study 
 
 
Thirty-two patients presented for secondary treatment following recurrence. This 
included 19 patients who came after treatment elsewhere and 13 patients who underwent 
surgical treatment in our institution for primary disease and subsequently had recurrence 
(Figure 2). Of these, 30 patients who underwent surgical treatment for recurrence of 
disease at our institution formed the secondary cases cohort, whist the two remaining 
patients who were treated with radiotherapy were excluded.  
 
Figure 2: Distribution of patients who received secondary treatment in CMC 
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PRIMARY CASES 
Demographics 
The primary cases comprised of 59 patients with a mean (SD) age of 17.08 (4.96) years 
and a range of 10 to 36 years (Figure 3). The majority (83.1%) were of the age group 
between 10-20 years. There were 8 patients from 21- 30 years and 2 were above 30 years 
(Table 1). All patients were male. 
Table 1: Age distribution of patients 
 
Age group Number of patients Percentage 
10-15 years 24 40.7 
16-20 years 25 42.4 
21-25 years 8 13.6 
26-30 years 0 0 
> 30 years 2 3.4 
Total 59 100 
 
 
Figure 3: Age distribution of patients (primary cases of JNA) 
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Symptomatology 
The commonest symptoms that the patients presented (Table 2) with were epistaxis 
(96.6%) and nasal obstruction (91.5%). Other symptoms included nasal discharge, 
headache, mouth breathing, diminished vision and hearing loss (Figure 4). 
 
Table 2: Spectrum of symptoms 
 
Symptom Number of patients Percentage 
Epistaxis 57 96.6 
Nasal obstruction 54 91.5 
Nasal discharge 33 55.9 
Headache 14 23.7 
Mouth breathing 16 27.1 
Diminished vision 3 5.1 
Hearing loss 4 6.8 
 
Figure 4: Symptomatology 
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The mean duration of symptoms prior to diagnosis was about 7-8 months for epistaxis, 
nasal obstruction, nasal discharge, headache and mouth breathing (Figure 5). The 
symptoms that signified advanced disease like diminished vision and hearing loss had a 
shorter duration of symptoms prior to presentation (Table 3). 
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Figure 5: Duration of symptoms 
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Table 3: Duration of symptoms 
Symptom No of patients 
(%) 
Mean duration of 
symptom (months) 
Standard 
deviation 
Range 
(months) 
Epistaxis 57 (96.6) 7.42 8.05 1 – 36 
Nasal obstruction 54 (91.5) 7.83 7.11 1 – 36 
Nasal discharge 33 (55.9) 6.79 4.87 1 – 24 
Headache 14 (23.7) 6.79 3.95 1 – 12 
Mouth breathing 16 (27.1) 8.12 7.63 1 – 24 
Diminished vision 3 (5.1) 2.67 0.58 2 – 3 
Hearing loss 4 (6.8) 2.75 2.22 1 – 6 
 
Over 60% of patients who presented with epistaxis or nasal obstruction (Table 4) sought 
medical treatment within 6 months of onset of symptoms (Figure 6). Nearly 20% of 
patients with epistaxis came for treatment within one month of onset of symptoms. 
However 12.3% of patients with epistaxis and 9.3% of patients with nasal obstruction had 
symptoms for more than 12 months prior to treatment and presented late. 
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Figure 6: Duration of epistaxis and nasal obstruction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Analysis of duration of epistaxis and nasal obstruction 
 
Duration of symptom No (%) of patients with 
epistaxis 
No (%) of patients with nasal 
obstruction 
Up to 1 month 11 (19.3) 4 (7.4) 
1 to 6 months 27 (47.4) 29 (53.7) 
6 to 12 months 12 (21.0) 16 (29.6) 
> 12 months 7 (12.3) 5 (9.3) 
 
 
Clinical signs 
 
All patients had a nasal as well as nasopharyngeal mass (Figure 7). Other signs included 
cheek swelling (28.8%), soft palate bulge (20.3%) and proptosis (5.1%).   
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Figure 7: Frequency of clinical signs 
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Extent of tumour 
Pre-operative computed tomography (CT) scans were done in 54 patients. In 5 patients, 
pre-operative scans were not done in view of clinically limited disease with endoscopic 
assessment. Of these 5 patients, 4 patients were found to have Stage I disease and 1 
patient Stage II disease intra-operatively.  
 
The nasal cavity and nasopharynx were found to be involved in all patients. Sphenoid 
sinus involvement was seen in 88% whilst the pterygopalantine fossa was involved in 
66% of patients. The anatomic locations in which the tumour had extended are 
summarized in Table 5. Extradural involvement was seen in 10 patients (16.9%) and 8 
patients (13.6%) had involvement of the cavernous sinus. The optic canal, foramen 
lacerum and pituitary fossa were not involved in any patient nor were intra-dural 
extension observed.  
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Table 5: Involved anatomic location of angiofibromas 
Location * Number Percentage 
Nasal cavity 59 100 
Nasopharynx 59 100 
Sphenopalantine region 53 88.1 
Sphenoid sinus 39 66.1 
Pterygoid palatine fossa 36 61.0 
Infratemporal fossa 29 49.2 
Ethmoid sinus 27 45.8 
Base of pterygoid  21 35.6 
Inferior orbital fissure 13 22.0 
Pterygoid plate 10 16.9 
Orbital apex 10 16.9 
Extradural extension 10 16.9 
Maxillary sinus 9 15.3 
Foramen rotundum  9 15.3 
Cavernous sinus 8 13.6 
Interpterygoid fossa 7 11.9 
Parapharyngeal space 6 10.2 
Superior orbital fissure 5 8.5 
Foramen ovale 3 5.1 
Anterior cranial fossa 2 3.4 
Clivus 1 1.7 
 
* None of the patients had involvement of the optic canal, foramen lacerum, pituitary fossa or intradural 
extension 
 
Fisch staging was used for the classification of JNA in this study. A small proportion of 
patients had early Stage I disease (13.6%). The majority of the cases operated were Stage 
II (37.3%) and Stage III (35.6%) disease and 13.6% of the patients had Stage IV tumour 
(Figure 8). 
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Figure 8: Stage of the disease 
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In this study, we observed that there was a trend (P=0.065) towards younger patients 
presenting with more advanced disease (Figure 9, Table 6).  
Figure 9: Correlation between stage of disease and age 
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Table 6: Correlation between stage of disease and age 
Stage of disease Number of patients Mean age in years Standard deviation 
Stage I 8 17.63 2.97 
Stage II 22 19.05 6.40 
Stage III 21 15.81 3.52 
Stage IV 8 14.5 3.46 
 
There was also a trend (P=0.099) towards a longer duration of epistaxis in patients with 
more advanced disease (Table 7). There was no association between the duration of nasal 
obstruction and stage of disease.  
 
Table 7: Correlation between duration of epistaxis and nasal obstruction and disease stage 
 
Stage of disease 
 
Number of patients 
Mean (SD) duration of 
epistaxis in months 
Mean (SD) duration of 
nasal obstruction in 
months 
Stage I 8 2.50 (2.33) 3.88 (3.23) 
Stage II 22 7.73 (9.25) 7.77 (8.46) 
Stage III 21 6.43 (5.96) 7.30 (6.79) 
Stage IV 8 12.25 (10.62) 9.38 (6.76) 
 
Arterial involvement on angiogram and embolization 
In patients with primary disease, the branches of the external and internal carotid artery 
were found to supply the tumour (Table 8). In the 31 patients who underwent angiogram 
and embolization, the internal maxillary artery was the major feeding vessel in all cases. 
Bilateral internal maxillary artery was the most common arterial supply (70.96%). The 
tumour was also supplied by ascending pharyngeal artery in 7 cases. Further vascular 
supply from the internal carotid artery (branches of ophthalmic artery, vidian artery and 
cavernous artery) was evident (Figure 10).  
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Table 8: Arterial involvement on angiogram 
 
Artery Branch involved Number of 
patients 
Percentage 
Ipsilateral internal maxillary artery 9 29.03 
Bilateral internal maxillary artery 22 70.96 
 
External carotid artery 
Ascending pharyngeal artery 7 22.58 
Ophthalmic artery 7 22.58 
Vidian artery 4 12.90 
Meningeal artery 2 6.45 
 
Internal carotid artery 
Cavernous artery 3 9.67 
 
 
 
Figure 10: Arterial involvement on angiogram 
9
22
7 7
4
2
3
0
5
10
15
20
N
um
be
r o
f p
at
ie
nt
s
Arterial involvement on angiogram
Arterial involvement
 Ipsilateral internal maxillary artery  Bilateral internal maxillary artery
Ascending pharyngeal artery Ophthalmic artery
Vidian artery Cavernous artery
 
 
Pre-operative embolization was performed in 31 patients (52.5%) before surgical 
resection (Figure 11). Branches of the external carotid artery were embolized whilst 
branches of the internal carotid artery were not embolized. Polyvinyl alcohol and gelform 
particles were used for embolization. 
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Figure 11: Pre-operative embolization 
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Surgical approaches 
All 59 patients selected for the study group underwent surgical excision of the tumour. 
The transpalatal approach was the most frequently used surgical approach (Table 9).  
Table 9: Overview of surgical approach 
Surgical approach Frequency Percent 
Transpalatal 17 28.8 
Endoscopic 10 16.9 
Lateral rhinotomy 10 16.9 
Transpalatal + sublabial 9 15.3 
Extended osteoplastic maxillotomy 5 8.5 
Infra temporal fossa approach 4 6.8 
Midfacial degloving 2 3.4 
Transpalatal + lateral rhinotomy 2 3.4 
Total 59 100 
 
When the surgical approach was categorized by staging, endoscopic surgery was the 
commonest treatment modality that was used in Stage I disease whilst transpalatal 
approach was the most frequent surgical approach for Stage II disease (Figure 12). 
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Different surgical approaches were used in Stage III disease whilst multiple surgical 
approaches were used for exposing the tumour in Stage IV disease (Figure 12).   
Figure 12: Surgical approach categorized by staging 
6
1 1
0 0 0 0 0
3
14
0
3
2
0 0 0
1
2
1
7
4
1
2
3
0 0 0 0
3
1
3
1
0
5
10
15
N
um
be
r o
f p
at
ie
nt
s
stage 1 stage 2 stage 3 stage 4
Surgical approach categorised by staging and type of surgery
Surgical approaches
Endoscopic Transpalatal
Mid-facial degloving Lateral rhinotomy
Transpalatal+sublabial Transpalatal+lateral rhinotomy
Extended osteoplastic maxillotomy Infra temporal fossa approach
 
 
Complications 
Comesis resulting after a Weber-Fergusson incision was acceptable in all patients. There 
was no per-operative mortality. The blood loss, as expected, was significantly higher 
(P=0.001) in patients with more advanced disease (Figure 13). There was no 
demonstrable effect of embolization on the volume of blood loss when patients were 
categorized according to the stage of disease and embolization (Figure 14). The mean 
(SD) blood loss was 660 (366) ml with the endoscopic approach (10 patients) and 685 
(510) ml with the transpalatal approach (Table 10). There was a significantly higher 
blood loss (P=0.02) in patients who underwent transpalatal and sublabial surgery (1856 ± 
1300 ml) compared with patients who underwent lateral rhinotomy (770 ± 519 ml).  
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Table 10: Type of surgical approach and blood loss 
Surgical approach No of patients Mean blood loss ( SD) Range 
Endoscopic 10 660 (366) 200 - 1300 
Transpalatal 17 685 (510) 200 – 1800 
Midfacial degloving 2 650 (71) 600 – 700 
Lateral rhinotomy 10 770 (519) 300 – 2000 
Transpalatal + sublabial 9 1856 (1300) 700 – 5000 
Transpalatal + lateral rhinotomy 2 1200 (566) 800 – 1600 
Extended osteoplastic maxillotomy 5 1900 (1575) 400 – 4000 
Infra temporal fossa approach 4 1625 (479) 1000 - 2000 
 
Figure 13: Blood loss correlated with staging of tumour  
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Figure 14: Blood loss categorized by stage and embolization 
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Other complications of surgery included nasal synechae in 22 patients, palatal fistula in 
10 patients and infections in 2 patients (Figure 15). 
Figure 15: Complications 
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Recurrence 
Of the 59 patients who presented with primary disease, 13 patients developed recurrence 
during the course of follow up. Of the 46 patients who did not have recurrence of disease, 
19 patients had a follow up of less than 12 months (Figure 16).  
Figure 16: Recurrence data 
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Recurrence seemed to occur primarily within the first 20 months of treatment for primary 
disease (Figure 17) 
Figure 17: Survival analysis of recurrence 
 
Recurrence tended to occur in younger patients although this did not reach statistical 
significance (Figure 18). A significant proportion of these (5/13, 38%) occurred within 6 
months of surgery for primary disease. Since younger patients tended to present with 
more advanced disease, it is possible that the recurrence occurring in younger patient 
could possibly be a reflection of more advanced disease. 
Figure 18: Correlation between age at presentation and recurrence 
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A higher proportion of patients with Stage III or Stage IV disease had recurrence (Figure 
19). However this again did not reach statistical significance (P=0.16).  
Figure 19: Staging of disease and recurrence 
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There was no association between pre-operative embolization and recurrence (6/28 
versus 7/31; no embolization versus embolization, P=1.0). When the type of surgical 
procedure and recurrence rate was evaluated, it was found that recurrence rate was 10% 
with the endoscopic approach (1/10). The patient with recurrence had stage III tumour. 
None of the patients with stage I and II tumour undergoing the endoscopic approach had 
recurrence. The combined transpalatal and sublabial approach was associated with the 
highest (5/9, 55.6%) recurrence rates, followed by midfacial degloving (1/2, 50%) and 
infratemporal approaches (2/4, 50%). In contrast, the recurrence rate of 10% (1/10) in 
patients who underwent the lateral rhinotomy approach, trended to be lower (P=0.057) 
when compared with the combined transpalatal and sublabial approach. The rate of 
recurrence was 20% (1/5) with the extended osteoplastic maxillotomy approach which 
was used for advanced tumour (stage III and stage IV).  
 46
Table 11: Type of surgical approach and recurrence 
Surgical approach Number with recurrence (%) Number without recurrence (%) 
Endoscopic 1 (10) 9 (90) 
Transpalatal 2 (11.8) 15 (88.2) 
Midfacial degloving 1 (50) 1 (50) 
Lateral rhinotomy 1 (10) 9 (90) 
Transpalatal + sublabial 5 (55.6) 4 (44.4) 
Transpalatal + lateral rhinotomy 0 (0) 2 (100) 
Extended osteoplastic maxillotomy 1 (20) 4 (80) 
Infra temporal fossa approach 2 (50) 2 (50) 
Total 13 (22.0) 46 (88.0) 
 
 
SECONDARY CASES 
Demographics of secondary cases 
The secondary cases comprised of 30 patients with a mean (SD) age of 17.4 (5.12) years 
and a range of 11 to 34 years (Figure 20). The majority (83.3%) were <20 years of age 
(Table 12). All patients were male. 
Table 12: Age distribution of patients 
 
Age group Number of patients Percentage 
10-15 years 12 40 
16-20 years 13 43.3 
21-25 years 2 6.7 
26-30 years 2 6.7 
> 30 years 1 3.3 
Total 30 100 
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Figure 20: Age distribution of patients (secondary cases of JNA) 
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Symptomatology 
The mean (SD) symptom free interval following previous surgery was 11.3 (10.82) 
months. The commonest symptoms that the patients with recurrent disease presented 
(Table 13) with were epistaxis (83.3%) and nasal obstruction (93.3%). Other symptoms 
included nasal discharge, headache, mouth breathing, diminished vision and hearing loss 
(Figure 21).  
 
Table 13: Spectrum of symptoms of patients with recurrent disease 
 
Symptom Number of patients Percentage 
Nasal obstruction 28 93.33 
Epistaxis 25 83.33 
Nasal discharge 11 36.66 
Mouth breathing 7 23.33 
Headache 6 20 
Hearing loss 4 13.33 
Diminished vision 1 3.33 
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Figure 21: Symptomatology of patients with recurrent disease 
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The mean duration of symptoms prior to diagnosis of recurrence was 7-10 months for 
epistaxis, nasal obstruction, nasal discharge and headache (Figure 22). The duration of 
diminished vision and hearing loss were much longer (12 months and 10.5 months 
respectively) probably reflecting persistence of symptoms of patients with primary 
disease (Table 14). About 50% of patients with recurrent disease presented within 6 
months of onset of epistaxis or nasal obstruction (Table 15). 
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Figure 22: Duration of symptoms in patients with recurrent disease 
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Table 14: Duration of symptoms in patients with recurrent disease 
Symptom No of patients 
(%) 
Mean duration of 
symptom (months) 
Standard 
deviation 
Range 
(months) 
Epistaxis 25 (83.3) 9.72 7.68 1 – 24 
Nasal obstruction 28 (93.3) 8.89 7.61 1 – 24 
Nasal discharge 11(36.33) 9.82 7.96 1 – 24 
Headache 6 (20.0) 7.18 8.54 2 – 24 
Mouth breathing 7 (23.33) 5.43 3.46 1 – 12 
Diminished vision 1 (3.33) 12 NA NA 
Hearing loss 4 (13.33) 10.5 3.0 6 - 12 
 
 
Table 15: Analysis of duration of epistaxis and nasal obstruction 
 
Duration of symptom No (%) of patients with 
epistaxis 
No (%) of patients with nasal 
obstruction 
Up to 1 month 4 (16) 6 (21.4) 
1 to 6 months 7 (28) 9 (32.1) 
6 to 12 months 9 (36) 8 (28.6) 
> 12 months 5 (20) 5 (17.9) 
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Clinical Signs 
On examination a nasal mass was seen in 28 (93.3%) patients whist a nasopharyngeal 
mass was seen in 29 (96.7%) patients (Figure 23). Cheek swelling was observed in 7 
patients (23.3%), soft palate bulge in 6 patients (20%) and proptosis in 3 patients (10%).  
Figure 23: Frequency of clinical signs 
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Extent of tumour 
Pre-operative computed tomography (CT) scans were done in all 30 patients. The nasal 
cavity, nasopharynx and sphenopalatine regions were most commonly involved. The 
anatomic locations that the tumour involved are summarized in Table 16. Extradural and 
cavernous sinus involvement was seen in 8 patients (26.7%). As with the primary cases, 
the optic canal, foramen lacerum and pituitary fossa were not involved in any patient nor 
were intra-dural extension observed.  
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Table 16: Involved anatomic location of recurrent angiofibromas 
Location * Number Percentage 
Nasopharynx 29 96.7 
Sphenopalatine region 29 96.7 
Nasal cavity 28 93.3 
Pterygoid palatine fossa 23 76.7 
Base of pterygoid  19 63.3 
Sphenoid sinus 19 63.3 
Infratemporal fossa 16 53.3 
Ethmoid sinus 11 36.7 
Inferior orbital fissure 10 33.3 
Pterygoid plate 8 26.7 
Interpterygoid fossa 8 26.7 
Cavernous sinus 8 26.7 
Extradural extension 8 26.7 
Foramen rotundum  7 23.3 
Parapharyngeal space 6 20 
Superior orbital fissure 4 13.3 
Orbital apex 4 13.3 
Maxillary sinus 3 10 
Foramen ovale 1 3.3 
Clivus 1 3.3 
 
* None of the patients had involvement of the optic canal, foramen lacerum, pituitary fossa, anterior cranial 
fossa or intradural extension 
 
Staging  
Stage I disease was seen in 16.7% of patients who presented with recurrence. The 
majority of the cases (Figure 24) operated were Stage II (26.7%), Stage III (30%) and 
Stage IV (26.7%). Unlike primary cases, there was no association between age and the 
stage of disease. There was also no correlation between the duration of epistaxis or nasal 
obstruction and the stage of disease (Table 17).   
 
Table 17: Correlation between age, duration of epistaxis and nasal obstruction and stage 
of disease 
 
Stage of disease 
Number of 
patients 
Mean (SD) age in 
months 
Mean (SD) duration 
of epistaxis in 
months 
Mean (SD) duration 
of nasal obstruction 
in months 
Stage I 5 17.20 (3.96) 5.20 (10.55) 7.80 (9.34) 
Stage II 8 18.88 (5.94) 10.50 (7.01) 10.50 (7.01) 
Stage III 9 17.00 (7.02) 6.67 (8.34) 5.89 (8.48) 
Stage IV 8 16.50 (2.14) 9.12 (7.06) 9.12 (7.06) 
 
 52
Figure 24: Stage of disease 
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Angiogram and embolization 
Eleven patients (36.7%) underwent pre-operative angiogram and embolization before 
surgery. As with primary cases, bilateral internal maxillary artery was the commonest 
arterial supply (63.63%). The other feeding vessels are summarized in Table 18. Again as 
with primary cases, only the branches of the external carotid artery were embolised.  
Table 18: Arterial involvement of secondary cases on angiogram 
 
Artery Branch involved Number of 
patients 
Percentage 
Ipsilateral internal maxillary artery 4 36.36 
Bilateral internal maxillary artery 7 63.63 
 
External carotid artery 
Ascending pharyngeal artery 2 18.18 
Ophthalmic artery 0 0 
Vidian artery 0 0 
Meningeal artery 1 9.09 
 
Internal carotid artery 
Cavernous artery 0 0 
 
Surgical approaches 
Thirty patients underwent surgical excision of the tumour. The transpalatal approach was 
the most frequently used surgical approach (Table 19).  
 53
Table 19: Overview of surgical approach of secondary cases 
Surgical approach Frequency Percent 
Transpalatal 8 26.67 
Lateral rhinotomy 6 20.0 
Transpalatal + sublabial 4 13.33 
Extended osteoplastic maxillotomy 4 13.33 
Endoscopic 3 10.0 
Infra temporal fossa approach 3 10.0 
Midfacial degloving 2 6.67 
Total 30 100 
 
Complications 
 
There was no operative mortality. The blood loss was significantly higher with Stage IV 
disease (1988 ± 1255 ml) compared with either Stage I (590 ± 219) or Stage II or III 
disease (Mean 800-850 ml). There was no difference in blood loss between embolized 
and non-embolized patients or with type of surgery. Nasal synechae developed in 46.7% 
of patients. Other complications included palatal fistula in 7 patients (23.3%), infection in 
2 patients and septal perforation and oronasal fistula in 1 patient each (Figure 25). 
Figure 25: Complications 
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Recurrence 
Of the 30 patients in the secondary disease cohort, 5 patients had further recurrence after 
surgical treatment (Figure 26). Of the 25 patients who did not have recurrence 8 patients 
were followed up for < 12 months. The mean (SD) duration of follow up of the secondary 
cases was 18.77 (23.79) months. 
Figure 26: Recurrence data of secondary cases 
 
 
There was no correlation between age of the patient and recurrence (P=0.5) nor was there 
any association between recurrence and the duration of epistaxis (P=0.15) or nasal 
obstruction (P=0.35). There were no further recurrences in patients who were treated for 
recurrent Stage I disease. The recurrence rates were higher in Stage IV disease (3 out of 5 
patients) although a statistically significant association between the stage of disease and 
recurrence was not evident (P=0.47). There were no differences in the recurrence rates 
amongst different surgical approaches. 
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DISCUSSION 
In this study we analyzed the clinical profile and the rate of recurrence of juvenile 
nasopharyngeal angiofibroma in patients who presented to our institution between 1998 
and 2008. There have been few reports of this disease from India14, 33, 34, 35 and this series 
would add to existing knowledge on JNA. In addition, this cohort contains patients who 
were treated by endoscopic surgery, a relatively new therapeutic option for this disease. 
We have also systematically analyzed patients with recurrent disease and have attempted 
to elucidate the factors that may contribute to recurrence.   
 
Symptomatology and signs 
The primary cohort consisted of patients of a young age group with a mean (SD) age of 
17.08 (4.96) years. This was very similar to other cohorts from India (Table 20). The 
commonest symptoms at presentation were epistaxis and nasal obstruction. This was 
again similar to other cohorts from India. Nasal mass was observed in all our patients 
whereas other studies have reported variable occurrence from 60-100%. A 
nasopharyngeal mass was almost universally seen in all series. 
 
Cheek swelling was seen only in 28.8% of our patients whilst another study from India35 
has reported this manifestation in 57.9% of patients. The incidence of proptosis was again 
much lower in our cohort (5.1%) compared with the cohort by Tyagi et al35 where the 
incidence was 21%.  
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Table 20: Comparison of demographics, symptoms and signs of primary cases 
Current study versus other Indian studies 
 
Parameter Current study Malik et al33 Mistry et al34 Tandon et al14 Tyagi et al35 
Number of primary cases 59 27 32 37 95 
Number of recurrent cases 30 NA NA 13 NA 
Mean (SD) age of primary 17.08 (4.96) 15.5 (NA) 16 (NA) 15.9 (NA) † NA 
Epistaxis (%) 96.6 96.3 NA 90 97.9 
Nasal obstruction (%) 91.5 92.6 NA 88 100 
Nasal mass (%) 100 88.9 NA 60† 89.4 
Nasopharyngeal mass (%) 100 100 NA 94 † 100 
Cheek swelling (%) 28.8 22.2 NA 10 57.9 
Soft palatal bulge (%) 20.3 NA NA NA 31.5 
Proptosis (%) 5.1 3.7 NA 14 21 
 
† Data for the entire cohort of 50 patients 
 
When we compare our data with Western data, we again find that the mean age of 
presentation of our patients was similar to other Western cohorts (Table 21). The 
incidence of epistaxis and nasal obstruction were higher in our cohort of patients (>90%) 
as compared with Western data (68-85%). One study from Egypt6 noted a high incidence 
of epistaxis (95%) comparable with our data (96.6%). Data on clinical signs were sparse 
in Western studies and hence could not be compared. 
 
Table 21: Comparison of demographics, symptoms and signs of primary cases  
Current study versus Western studies 
 
Parameter Current 
study 
Pryor  
et al5 
Hardillo 
et al12 
El-Banhawy 
et al6 
Economou 
et al36 
Number of primary cases 59 58 29 20 83 
Number of recurrent cases 30 7 NA NA NA 
Mean (SD) age of primary 17.08 (4.96) 15 17.9 (NA) 15.5 (NA) 17(NA) 
Epistaxis (%) 96.6 85 79.31 95 73 
Nasal obstruction (%) 91.5 68 82.8 75 71 
Nasal mass (%) 100 NA NA NA NA 
Nasopharyngeal mass (%) 100 NA NA NA NA 
Cheek swelling (%) 28.8 NA NA NA NA 
Soft palatal bulge (%) 20.3 NA NA NA NA 
Proptosis (%) 5.1 14 NA NA 7 
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Surprisingly duration of symptoms was higher in secondary cases when compared to 
primary cases. Mean duration of alarming symptom like epistaxis was 9.7 months in 
secondary cases. Reasons for this are unclear and this need to be further studied. 
 
Extent of tumour 
 
The nasal cavity and nasopharynx were involved in all our patients. In a study done by 
Tyagi et al35 the nasopharynx was involved in 100% and nasal cavity in 89.4%. The 
sphenopalatine region, sphenoid sinus and pterygopalatine fossa were involved in more 
than 50% of our patients. None of our patients had involvement of the optic canal, 
foramen lacerum, pituitary fossa or intradural extension.  
 
Intracranial extension was seen in 16.9% and 26.7% patients in primary cases and 
secondary cases respectively. Economou et al36 reported intracranial extension in 21% of 
patients. About 50% of our patients presented with advanced disease (Stage III or IV). 
Comparison of staging of disease with other Indian cohorts was made difficult by the fact 
that several other staging systems were used. In a comparable cohort that used the Fisch 
classification, advanced disease was observed in 33% of patients.37 In another study by 
Andrews et al,18  30% of patients presented with advanced disease. 
 
In primary cases, we observed that there was a trend towards younger patients presenting 
with more advanced disease but there was no correlation between age and stage in 
secondary cases. An association between age and stage of disease has been demonstrated 
in other case series. Tandon et al14 observed that tumours tended to grow slower in 
patients who are in their late teens or early twenties, than in patients of 15 years or 
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younger. In primary cases there was also a trend towards a longer duration of epistaxis in 
patients with more advanced disease, but no such trend seen in secondary cases.  
 
Arterial involvement on angiogram 
In the current study, the internal maxillary artery was the major feeding vessel in all 
patients who underwent an angiogram. An interesting aspect in our study was that 
bilateral internal maxillary arterial supply to the tumour was more commonly observed 
(71%) than ipsilateral internal maxillary arterial supply (29%). In contrast, Nicoli et al37 
in their cohort of 15 patients observed that 73.4% of patients had strictly unilateral 
vascular supply and only 26.6% had contralateral feeding vessels.  
 
Surgical approaches 
A range of surgical approaches were used in the management of JNA, reflecting a diverse 
approach by a large team of surgeons as well as changing surgical trends over time. It is 
interesting to note that our cohort had 10 patients who were treated with the more 
recently described endoscopic surgical approach. Small cohorts of endoscopically treated 
JNA are described in literature. Roger et al27 have treated 20 cases with purely 
endoscopic resection. In our small cohort of patients, one of the 10 patients (10%) had 
recurrence of disease, 6 months after the initial procedure.  
 
The traditional transpalatal approach was the commonest approach that was used in our 
patients with Stage II disease. Extensive surgical approaches were used for advanced 
stage disease. The type of surgical approach was based on several factors that included 
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(a) the stage of tumour, (b) age of the patient (growth of craniofacial skeleton) (c) 
morbidity of the approach and (d) the tendency of tumour to become involuted or 
stabilized with maturity.35  
 
Blood loss 
In our study, the mean (SD) blood loss was not different between primary and secondary 
cases (1057 (909) versus 1095 (916) ml). In the study by Tandon et al,14 the mean blood 
loss was 1057 ml in 50 patients. In our study, the patients who underwent endoscopic 
surgery, had a mean blood loss of 660 ml (n=10) and 733 ml (n=3) for primary and 
secondary cases respectively. In a study by Onerci et al,30 the mean blood loss was 1000 
ml in 8 patients operated by the endoscopic approach. Roger at el27 reported a much 
lower blood loss of 350 ml in 20 patients undergoing endoscopic surgery. The mean 
blood loss with the transpalatal approach was similar between our cohort and the study 
reported by Tandon et al14 (685 ml versus 843 ml). In our study, a significantly higher 
blood loss (P=0.02) was noted in patients who underwent transpalatal and sublabial 
surgery (1856 ± 1300 ml) compared with patients who underwent lateral rhinotomy (770 
± 519 ml). The blood loss was significantly higher in patients with more advanced 
disease (Figure 13). Similarly Radkowski et al11 found that there was a noticeable trend 
toward increased blood loss with increasing preoperative stage.  
 
There was no demonstrable effect of embolization on the volume of blood loss in both 
primary and secondary cases. A similar effect was noted by Petruson et al2 who observed 
that pre-operative embolization did not impact blood loss (1300 versus 1250 ml, 
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embolized versus non-embolized group respectively). Glad et al7 found that preoperative 
embolization significantly decreased the intraoperative blood loss (mean blood loss was 
650ml in embolized group compared to 1200 ml in non embolized group. It is unclear at 
this stage if pre-operative embolization reduces intra-operative blood loss in patients with 
JNA.  
 
Recurrence 
In our study, the recurrence rate was 22% in primary cases and 16.7% for secondary 
cases. The mean (SD) duration of follow up were 16.95 (20.32) and 18.77 (23.79) months 
for primary and secondary cases respectively. Recurrence seemed to occur primarily 
within the first 20 months of treatment for primary cases. The recurrence rates are similar 
to other published cohorts (Table 22) 
Table 22: Recurrence rates 
 Rate of recurrence in primary 
cases 
Rate of recurrence in secondary 
cases 
Current study 22% 16.7% 
Herman et al19 27.5% NA 
Mann et al8 25% 40% 
Radkowski et al11 22% NA 
 
In our study, recurrence tended to occur in the younger patients (Table 13) and this is 
similar to observations by Petruson et al.2 It is possible that recurrence in younger 
patients is a reflection of more advanced disease in younger patients. The presence or 
duration of any of the symptoms or signs did not predict recurrence.  
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Table 23: Univariate analysis of factors that predict recurrence 
 
Patients with recurrence  
(n=13) 
Patients without 
recurrence (n=46) 
 
Continuous variables 
Mean SD Mean SD 
 
P value 
Age (years) 15.38 3.66 17.56 5.20 0.05* 
Duration of epistaxis (months) 7.38 9.04 7.43 7.84 0.51 
Duration of nasal obstruction (months) 6.61 5.90 8.22 7.47 0.78 
Stage of tumour 2.77 1.01 2.41 0.86 0.13 
 
 
 
Discrete variables 
Patients with recurrence  
(n=13) 
Patients without recurrence 
(n=46) 
P value 
History 
         Epistaxis 
         Nasal obstruction 
         Nasal discharge 
         Mouth breathing 
         Headache 
         Decreased vision 
         Hearing loss 
 
13 
13 
8 
3 
6 
2 
0 
 
44 
41 
25 
13 
8 
1 
4 
 
1.0 
0.57 
0.76 
1.0 
0.06 
0.12 
0.57 
Signs 
        Nasal/NP mass 
        Cheek swelling 
        Palatal bulge 
        Proptosis 
 
13 
5 
3 
2 
 
46 
12 
9 
1 
 
1.0 
0.49 
0.72 
0.12 
 
The pre-operative tumour stage was not found to be significantly associated with 
recurrence in our cohort of patients. Radkowski et al11 found that preoperative tumour 
stage was the primary factor affecting tumour recurrence. 
 
Some studies have reported increased risk of recurrence with pre-operative embolization. 
Lloyd et al31 reported that embolization was a contributory cause of recurrence as it 
shrinks the tumour making total removal more difficult especially if there is deep 
invasion of sphenoid, and concluded that patients who showed this on preoperative CT 
are at high risk of recurrence and embolization is contraindicated. In the study by 
Petruson et al,2 7 patients (41%) who were treated with preoperative embolization had a 
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recurring tumour compared to only 1 patient (8%) in the non-embolized group. We did 
not however note an association between embolization status and recurrence.  
 
The association between the choice of surgical approach and recurrence rates is 
important. Analysis of recurrence is mandatory to validate the choice of any surgical 
approach, but this is difficult because JNA is a rare disorder. In our study, with the 
endoscopic approach only 1 patient had recurrence out of 10. This patient had stage III 
tumour. None of the patients with stage I and II tumour who were operated with the 
endoscopic approach had recurrence. These results indicate that endoscopic approach is 
as effective as open surgery for early stage tumour. Possibly for late stage tumours 
endoscopic approach may not be ideal as resection may not be complete and technically 
difficult.   
 
Onerci et al30 used endoscopic technique in early and late stage (minimal intracranial 
extension) angiofibroma. They were able to excise tumour completely in early stage 
tumour. However some residual tumour was observed in late stage tumour. They 
suggested that in late stage tumour, the surgeon must be prepared to shift or use 
combined technique, otherwise there is a possibility for extensive residual lesion. Lateral 
tumour extension to cavernous sinus or optic nerve, extensive extension to middle cranial 
fossa and posterior to pterygoid plates are definite limits for endoscopic surgery. 
 
In our cohort, the combined transpalatal and sublabial approach was associated with the 
highest (5/9, 55.6%) recurrence rates, followed by midfacial degloving (1/2, 50%) and 
 63
infratemporal approach (2/4, 50%). In contrast the recurrence rate was only 10% (1/10) in 
patients who underwent the lateral rhinotomy approach. Similar results were reported by 
Radkowski et al11 in which the combined transpalatal and transantral approach was 
associated with a 75% recurrence rate compared with a 9.1% recurrence rate with lateral 
rhinotomy approach. The rate of recurrence was 20% (1/5) in our study with extended 
osteoplastic maxillotomy approach which was used for advanced tumour (stage III and 
stage IV). 
 
Tyagi et al35 found that extension into the pterygoid fossa and basisphenoid, erosion of 
the clivus, intracranial extension medial to cavernous sinus, invasion of sphenoid dipole 
through a widened pterygoid canal were associated with an increase risk of recurrence. In 
our study we did not found any significant association of these areas and recurrence. 
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CONCLUSIONS 
 
*  The most common presenting symptoms were epistaxis and nasal obstruction in 
both primary and secondary cases. 
 
 
* More advanced disease was observed in younger patients and in those who had a 
longer duration of epistaxis. 
 
 
 
* Intra-operative blood loss was significantly higher in patients with more advanced 
disease. 
 
 
* There was no effect of pre-operative embolization on intra-operative blood loss.  
 
 
* The blood loss was significantly higher in patients who underwent surgery by the 
combined transpalatal and sublabial approach compared with the lateral 
rhinotomy approach. 
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*  The mean (SD) symptom free interval following previous surgery was 11.3 
(10.82) months in secondary cases. 
 
 
* Younger patients had a tendency for recurrence. 
 
 
* There was no association between embolization and recurrence in both primary 
and secondary cases. 
 
 
* The rate of recurrence was higher with the combined transpalatal and sublabial 
approach when compared to the lateral rhinotomy approach. 
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Informed Consent form to participate in an observational study 
 
Study Title: “Clinical profile of Juvenile nasopharyngeal angiofibroma and analysis of 
recurrences”  
 
Study Number: 
 
Subject’s Initials: _________   Subject’s Name: ________ 
Date of Birth / Age:_______ 
 
Please initial box (Subject) 
 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [ ] 
 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published. [ ] 
 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
 
(v) I agree to take part in the above study. [ ] 
 
 
 
 
Date Signature (or Thumb impression) of the 
Subject/Legally Acceptable Representative 
 
Signatory’s Name:  
 
 
 
Date      Signature of the investigator 
      Study investigators name: 
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Informed Consent form to participate in an observational study 
(For paediatric patient) 
 
Study Title: “Clinical profile of Juvenile nasopharyngeal angiofibroma and analysis of 
recurrences”  
 
Study Number: 
 
Subject’s Initials: _________   Subject’s Name: ________ 
Date of Birth / Age:_______ 
 
Please initial box (Subject) 
 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
 
(ii) I understand that my child’s participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without his medical care or legal rights 
being affected. [ ] 
 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. However, I understand that my child’s identity will not be revealed in any 
information released to third parties or published. [ ] 
 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
 
(v) I agree that my child can take part in the above study. [ ] 
 
 
 
 
Date Signature (or Thumb impression) of the 
Subject/Legally Acceptable 
Representative/Guardian 
 
Signatory’s Name:  
 
 
 
Date      Signature of the investigator 
      Study investigators name: 
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Patient Information sheet 
 Study Title:  
 
Clinical profile of Juvenile nasopharyngeal angiofibroma (nasal tumour) and analysis of 
recurrences  
Purpose of research:  
1. To study  the symptoms and signs of patients diagnosed to have this nasal 
tumour 
2. To assess factors that may have contributed to recurrence of tumour 
Expected duration of the Subject’s participation:  
Duration of study will be 18 months.  
Description of the procedures: 
This study would not involve any additional procedures or treatments 
However treatments that are required as part of your regular follow up, such as scans and 
endoscopy, may be required and advised by your surgeon irrespective of whether you are 
part of the study or not. This would be determined by your treating surgeon. 
Risks or discomforts to the Subject:    
As the study does not include any trial treatment, there is no extra risk for the patient due to 
participation in study and there will not be any additional cost of treatment for the patient. 
Benefits to the Subject:  
Since you have presented for an evaluation by the ENT surgeon, the surgeon might be able to 
pick up any evidence of residual disease or recurrence. However if you have come for your 
routine follow up, there is no additional benefit to you. 
Benefits to others:  
The potential benefit for others is what new knowledge that we might gain in studying all the 
factors that might predict recurrence.  
Confidentiality:  
 
Patient’s identity will not be revealed in any information or released to third parties or 
published.  
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Participation:   
 
Your participation in the study is entirely voluntary and the patient is free to withdraw at any 
time, without giving any reason. Refusal to participate will not involve any penalty or loss of 
benefits to which the Subject is otherwise entitled. 
 
Contact person:  
 
Dr Sunil Jalan, Dept of E.N.T., CMCH, Vellore 
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PROFORMA 
NAME                                                                                             HOSPITAL NO. 
AGE                                                                                                   SEX 
 
ADRESS 
 
PHONE NO. 
 
DATE OF ADMISSION 
 
DATE OF SURGERY 
 
DATE OF DISCHARGE 
 
HISTORY OF PREVIOUS SURGERY            YES (1)                                                            NO (2)  
IF YES DATE OF SURGERY 
 
SYMPTOM FREE INTERVAL FOLLOWING SURGERY (IN MONTHS) -   
 
SURGICAL APPROACH 
Endoscopic 1 
Transpalatal 2 
Lateral rhinotomy 3 
Mid facial degloving 4 
Extended osteoplastic maxillectomy 5 
Infratemporal fossa approach 6 
Endoscopic assisted 7 
other 8 
 
Symptoms   
 
YES (1) NO
(2) 
IF YES 
Duration (In months) 
Epistaxis    
Nasal obstruction    
Nasal discharge    
Obligatory mouth breathing    
Headache    
Otalgia    
Dysphagia    
Blindness    
Hearing loss    
 
Signs YES (1) NO (2) 
Nasal mass   
Nasopharyngeal mass   
Cheek swelling   
Bulged soft palate   
Proptosis   
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Investigations- 
HB -          GM% 
 
RIGID NASAL ENDOSCOPY:  If done (1)          Not done (2)  
If done 
Nasal cavity (1)     nasopharynx (2)  
 
CT SCAN –  
 
Location  Yes(1) No(0) 
Nasal cavity   
Nasopharynx   
Sphenopalatine region   
Sphenoid sinus   
Pterygoid palatine fossa   
Infratemporal fossa   
Ethmoid sinus   
Base of pterygoid    
Inferior orbital fissure   
Pterygoid plate   
Orbital apex   
Extradural extension   
Maxillary sinus   
Foramen rotundum    
Cavernous sinus   
Interpterygoid fossa   
Parapharyngeal space   
Superior orbital fissure   
Foramen ovale   
Anterior cranial fossa   
Clivus   
 
 
CT STAGING 
STAGE I 1 
STAGE II 2 
STAGE III 3 
STAGE IV 4 
 
Angiography                done (1)                             not done (2) 
If done  
 Supplying vessel 
Int maxillary artery (1)      ascending pharyngeal artery (2) 
 
 Embolization                YES (1)                                 NO (2)  
 If yes  
 Material used for embolization 
 Gel (1)          Alcohol (2) 
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Surgical approach 
Endoscopic 1 
Transpalatal 2 
Mid facial degloving 3 
Lateral rhinotomy 4 
Transpalatal+ Sublabial 5 
Transpalatal+ Lateral rhinotomy 6 
Extended osteoplastic maxillectomy 7 
Infratemporal fossa approach 8 
 
Intraop blood loss      ……..      ml 
 
Duration of surgery: …….      hrs 
 
Intraop blood transfusion    YES (1)                      NO (2)  
         IF YES       ………ML 
 
Postop blood transfusion    YES (1)                      NO (2)  
         IF YES       ………ML 
 
Duration of stay in surgical ICU ---       Days 
 
Duration of total in patient stay   ………. Days 
 
Anterior nasal pack removal   ….     Post op day 
 
Posterior nasal pack removal ……. Post op day 
 
 
Complication YES ( 1 ) NO ( 2 ) 
Palatal fistula   
Wound infection   
Nasal synechae   
CSF leak   
Mal occlusion   
Residual disease                 
 
Follow up 
Follow up period ….         Months 
 
Recurrence                      YES (1)                            NO (2)  
IF yes  
SYMPTOM FREE INTERVAL FOLLOWING SURGERY (IN MONTHS) – 
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1 031300D 20/06/2007 0 35 1 5 1 5 1 5 0 0 0 0 0 0 0 0 1 1 0 0 0 2 1 4 500 0 0 0 
2 837122C 08/10/2006 1 11 1 8 1 5 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 4 1 7 4000 0 1 1 
3 080434C 23/10/2001 0 12 1 6 1 6 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 2 0 2 400 0 0 0 
4 852268C 07/11/2006 0 18 1 1 1 2 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 1 300 0 0 0 
5 257706C 21/02/2003 0 14 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 2 0 2 200 1 0 0 
6 642674B 08/03/1998 1 22 1 6 1 6 1 6 0 0 0 0 0 0 0 0 1 1 0 0 0 3 0 5 700 0 0 0 
7 940359B 01/10/2000 0 15 1 8 1 8 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 4 1 5 1500 0 0 0 
8 190856D 08/01/1900 0 17 1 7 1 7 1 7 0 0 0 0 0 0 0 0 1 1 1 0 0 3 0 4 400 0 0 0 
9 283606D 10/09/2008 0 17 1 10 1 10 1 4 0 0 0 0 0 0 0 0 1 1 0 0 0 3 1 4 500 0 0 0 
10 928021B 03/07/2002 0 19 1 8 1 6 1 6 0 0 0 0 0 0 1 1 1 1 1 0 0 4 1 6 1600 1 0 0 
11 992544B 03/09/2001 1 13 1 3 1 4 1 3 0 0 0 0 1 3 0 0 1 1 1 0 0 3 1 8 1500 0 0 0 
12 742758B 06/11/1999 1 14 1 6 1 6 1 6 1 6 0 0 1 2 0 0 1 1 0 1 1 3 1 4 1200 1 0 0 
13 617396C 04/07/2005 0 20 1 2 1 3 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 3 1 4 1000 1 0 0 
14 311077C 06/04/2003 0 14 1 8 1 8 0 0 1 8 1 8 0 0 0 0 1 1 0 0 0 2 0 2 1800 0 0 0 
15 945376C 17/01/2007 0 14 1 24 1 24 1 12 1 12 1 24 0 0 0 0 1 1 0 0 0 3 1 7 1600 1 0 0 
16 985194B 02/02/2001 1 18 1 5 1 5 1 5 1 4 0 0 0 0 0 0 1 1 0 0 0 2 0 2 200 1 1 0 
17 639751c 06/10/2005 0 16 1 2 1 2 1 2 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 1 1100 0 0 0 
18 310594C 07/01/2003 0 24 1 36 1 36 0 0 1 12 0 0 0 0 0 0 1 1 0 1 0 2 0 2 500 0 0 1 
19 129919C 03/05/2002 0 17 1 24 1 12 1 12 0 0 0 0 0 0 0 0 1 1 0 0 0 2 0 2 1600 0 1 0 
20 688903C 09/09/2005 0 17 1 1 1 2 1 1 0 0 1 1 0 0 0 0 1 1 0 0 0 1 0 1 500 0 0 0 
21 099680D 18/09/2007 0 16 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 2 0 2 400 0 0 0 
22 289722D 21/08/2008 0 14 1 6 1 6 0 0 0 0 1 3 0 0 0 0 1 1 1 1 0 3 1 4 600 0 0 0 
23 546589C 22/11/2004 0 13 1 4 1 4 1 4 0 0 0 0 0 0 0 0 1 1 0 0 0 2 1 2 750 0 0 0 
24 192403C 09/03/2002 0 11 1 3 1 10 1 6 0 0 0 0 0 0 0 0 1 1 1 1 0 3 0 2 250 0 0 0 
25 030815D 07/11/2007 0 20 1 24 1 24 1 24 0 0 1 24 0 0 0 0 1 1 0 0 0 2 1 4 800 1 0 0 
26 933376C 12/07/2006 1 13 1 1 1 1 0 0 1 1 1 1 0 0 0 0 1 1 0 0 0 3 1 8 1000 0 0 0 
27 797561B 30/09/1999 1 19 1 3 1 3 1 3 1 6 0 0 0 0 0 0 1 1 0 0 0 1 0 3 600 1 0 0 
28 992502C 16/05/2007 0 13 1 1 1 1 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 3 1 7 400 0 0 0 
29 836850B 18/01/2000 1 18 1 12 1 12 1 12 0 0 0 0 0 0 0 0 1 1 0 0 0 2 0 5 800 0 1 0 
30 702003C 11/03/2005 0 13 1 12 1 3 1 3 0 0 1 2 0 0 0 0 1 1 1 1 0 3 1 4 2000 0 0 0 
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31 772319C 03/10/2006 0 12 1 6 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 3 1 4 300 1 0 0 
32 143727C 04/10/2002 0 16 0 0 1 10 1 10 1 6 1 10 0 0 0 0 1 1 0 0 0 1 0 1 1300 0 0 0 
33 981898C 03/02/2007 0 22 0 0 1 12 1 12 1 12 1 12 0 0 0 0 1 1 0 0 0 2 0 5 900 1 1 0 
34 869083C 09/05/2006 0 17 1 3 1 3 1 3 0 0 0 0 0 0 1 2 1 1 0 0 0 2 0 1 300 0 0 0 
35 956232B 14/11/2000 0 15 1 2 1 2 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 2 0 2 1500 0 0 0 
36 995342C 04/04/2007 0 15 1 12 1 12 1 12 0 0 0 0 0 0 0 0 1 1 1 0 0 4 1 7 3000 1 0 0 
37 305811D 25/09/2008 0 17 1 18 1 12 0 0 0 0 1 12 0 0 1 2 1 1 1 1 0 4 1 8 2000 0 1 0 
38 669603B 15/10/1998 0 14 1 3 1 2 1 2 0 0 1 2 0 0 0 0 1 1 0 0 0 2 0 2 500 1 0 0 
39 482841C 13/07/2004 1 18 1 36 1 24 1 12 1 12 1 12 0 0 0 0 1 1 1 0 0 4 1 5 5000 1 1 0 
42 946311C 01/11/2007 0 24 1 6 1 6 1 6 1 6 0 0 0 0 0 0 1 1 0 0 0 1 0 1 200 0 0 0 
40 863844C 22/08/2006 0 13 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 2 1 1 500 0 0 0 
41 833488C 13/07/2006 0 24 1 3 1 3 1 3 0 0 1 3 0 0 0 0 1 1 0 0 0 2 1 2 500 0 0 0 
43 533029C 26/10/2004 0 23 1 12 1 12 1 12 0 0 0 0 0 0 0 0 1 1 0 1 0 3 1 8 2000 1 0 0 
44 841751B 01/05/2000 0 36 1 12 1 12 1 12 0 0 0 0 0 0 0 0 1 1 0 0 0 2 1 4 400 0 0 0 
45 845322C 07/03/2006 1 16 1 3 1 3 0 0 0 0 1 3 0 0 0 0 1 1 0 0 0 3 1 1 900 0 0 0 
46 129501C 04/05/2002 1 10 1 3 1 3 1 2 1 3 0 0 0 0 0 0 1 1 1 1 0 4 1 5 2000 1 0 0 
47 670186B 20/10/1998 0 22 1 12 1 12 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 2 0 2 300 0 0 0 
48 000758C 27/03/2001 0 19 1 6 1 6 1 6 1 6 0 0 0 0 0 0 1 1 1 0 0 3 0 5 2200 1 0 0 
49 296310D 16/09/2008 0 15 1 18 1 12 0 0 0 0 1 12 0 0 1 6 1 1 1 1 0 3 1 3 700 1 0 0 
50 755910C 23/01/2006 0 14 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 700 0 0 0 
51 245949C 15/01/2003 0 21 1 2 1 2 1 2 0 0 0 0 0 0 0 0 1 1 0 0 0 2 1 2 600 1 0 0 
52 937451B 26/09/2000 0 20 1 1 0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 3 0 2 1100 1 1 0 
53 017660D 05/10/2007 0 18 1 3 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 3 1 6 800 0 0 0 
54 900189B 30/06/2000 0 17 1 1 1 24 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 3 0 5 1800 1 1 0 
55 155470C 16/05/2002 1 11 1 4 1 8 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 3 0 5 1800 0 0 0 
56 307481C 14/08/2003 0 18 1 1 1 4 1 4 0 0 0 0 0 0 0 0 1 1 0 0 0 2 0 2 750 1 1 0 
57 161274C 05/02/2006 0 16 1 5 1 5 1 5 0 0 0 0 0 0 0 0 1 1 0 0 0 2 1 1 800 0 0 0 
58 280247D 08/07/2008 0 11 1 5 1 5 0 0 0 0 0 0 1 3 0 0 1 1 1 0 1 4 1 7 500 0 0 0 
59 168407C 07/09/2002 1 17 1 6 1 6 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 2 300 0 0 0 
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NO NAME H.NO NC SPF NPX MS ES SS TPF PP BASE INT
ER 
ITF IOF SO
F 
OA OC PPS FO FR F
L 
EXT
RA 
CS ID PIT ACF CLI CRIB 
1 ABHIGIT ROY 031300D 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 ABHIJIT MANDAL 837122C 1 1 1 0 1 1 1 0 1 0 1 1 0 1 0 0 0 1 0 1 1 0 0 1 0 1 
3 ABISHEK KUMAR 080434C 1 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4 ARDHENDU HATI 852268C 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
5 BALASUBRAMANIAM.B.C. 257706C 1 1 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
6 BENIMADHAB 642674B 1 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
7 CHUTTAN RAJWAR 940359B 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 0 1 1 0 0 0 0 0 
8 DEB KUMAR SANTRA 190856D 1 1 1 1 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
9 DHANANJAY KUMAR 283606D 1 1 1 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
10 DHARMENDRA 928021B 1 1 1 0 1 1 1 1 1 1 1 1 0 0 0 1 1 1 0 1 1 0 0 1 1 0 
11 DIPANKAR MAJUMDAR 992544B 1 1 1 0 0 1 1 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
12 GOUTAM KUMAR MAITY 742758B 1 1 1 0 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
13 JATIN MAJI 617396C 1 1 1 1 1 1 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
14 JAYANTA KONAR 311077C 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
15 KAUSHAL KUMAR 945376C 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
16 KIRAN BAG DAS 985194B 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
17 KUMAR 639751c 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
18 MADHABANANDA 310594C 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
19 MAHADEB SAUTYA 129919C 1 1 1 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
20 MANOJ DHUA 688903C 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
21 MD MOQARIM 099680D 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
22 MITHILESH RUPAL SHARMA 289722D 1 1 1 1 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
23 MOHAMMED SADDAM HUSSAIN 546589C 1 1 1 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
24 NARAYAN DAS 192403C 1 1 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
25 NAVIN KUMAR 030815D 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
26 PALLAB JOSH 933376C 1 1 1 0 1 1 1 0 0 1 1 1 0 1 0 1 1 0 0 1 0 0 0 0 0 0 
27 PARANTHAMAN 797561B 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
28 PRABU R. 992502C 1 1 1 0 1 1 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
29 PRADEEP KU RATREY 836850B 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
30 PRAVEEN KUMAR PANDE 702003C 1 1 1 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
31 RAHUL KARMAKAR 772319C 1 0 1 1 0 1 0 0 1 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 
32 RAJKUMAR BEJ 143727C 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
33 RANJIT GHORAI 981898C 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
34 RAVI SHANKAR 869083C 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
35 REDDAPPA 956232B 1 1 1 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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36 ROHIT KUMAR 995342C 1 1 1 0 1 1 1 1 1 1 1 1 1 1 0 1 1 1 0 1 1 0 0 0 0 0 
37 SABU CHANDRA ROY 305811D 1 1 1 0 1 1 1 0 1 0 1 1 1 1 0 0 0 1 0 1 1 0 0 0 0 0 
38 SAMIR NARAYAN JAMADAR 669603B 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
39 SANJIB XESS 863844C 1 0 1 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
42 SANJIV KUMAR 482841C 1 1 1 0 1 1 1 1 0 0 1 0 1 1 0 1 0 1 0 1 1 0 0 0 0 0 
40 SANJOY GHOSH 946311C 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
41 SATHEESH KUMAR 833488C 1 1 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
43 SENTHIL 533029C 1 1 1 0 1 1 1 0 1 0 1 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 
44 SHANMUGAM 841751B 1 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
45 SHASHI SHAW 845322C 1 1 1 0 0 1 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
46 SHEIK AFSAR 129501C 1 1 1 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 
47 SHYMAL SAHA 670186B 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
48 SIVA KUMAR 000758C 1 1 1 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
49 SK. BILAL HOSSAN 296310D 1 1 1 0 1 1 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
50 SUDIP GHORAI 755910C 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
51 SUJOY SARKAR 245949C 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
52 SUMAN DAS 937451B 1 1 1 1 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
53 SUMAN PAL 017660D 1 1 1 0 1 1 1 0 1 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
54 SUMED KUMAR MONDAL 900189B 1 1 1 0 1 1 1 0 0 1 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 
55 SUMIT DAS 155470C 1 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
56 SURESH M 307481C 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
57 TANMOY CHOWDHARY 161274C 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
58 UTTAM DAS 280247D 1 1 1 1 1 1 1 0 1 0 1 1 1 1 0 0 0 1 0 1 1 0 0 0 0 0 
59 VENKETESAN 168407C 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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NO NAME 
HOSPITAL 
NO DOS EMB 
I/L 
IMA 
B/L 
IMA APA OPH VIDI MENIN CAVER PVA GELF 
1 ABHIGIT ROY 031300D 20/6/2007 1 0 1 0 0 0 0 0 0 1 
2 ABHIJIT MANDAL 837122C 10/8/2006 1 1 0 0 0 0 0 0 1 1 
3 ABISHEK KUMAR 080434C 23/10/2001 0 0 0 0 0 0 0 0 0 0 
4 ARDHENDU HATI 852268C 11/7/2006 0 0 0 0 0 0 0 0 0 0 
5 BALASUBRAMANIAM.B.C. 257706C 21/02/2003 0 0 0 0 0 0 0 0 0 0 
6 BENIMADHAB 642674B 3/8/1998 0 0 0 0 0 0 0 0 0 0 
7 CHUTTAN RAJWAR 940359B 10/1/2000 1 0 1 1 1 1 1 0 0 1 
8 DEB KUMAR SANTRA 190856D 21/4/2008 0 0 0 0 0 0 0 0 0 0 
9 DHANANJAY KUMAR 283606D 9/10/2008 1 0 1 0 0 0 0 0 0 1 
10 DHARMENDRA 928021B 7/3/2002 1 0 1 1 0 0 0 0 0 1 
11 DIPANKAR MAJUMDAR 992544B 9/3/2001 1 0 1 0 1 0 0 0 0 1 
12 GOUTAM KUMAR MAITY 742758B 11/6/1999 1 1 0 1 0 1 0 0 0 1 
13 JATIN MAJI 617396C 7/4/2005 1 0 1 0 0 0 0 0 0 1 
14 JAYANTA KONAR 311077C 4/6/2003 0 0 0 0 0 0 0 0 0 0 
15 KAUSHAL KUMAR 945376C 17/01/2007 1 0 1 0 0 0 0 0 0 1 
16 KIRAN BAG DAS 985194B 2/2/2001 0 0 0 0 0 0 0 0 0 0 
17 KUMAR 639751c 10/6/2005 0 0 0 0 0 0 0 0 0 0 
18 MADHABANANDA 310594C 1/7/2003 0 0 0 0 0 0 0 0 0 0 
19 MAHADEB SAUTYA 129919C 5/3/2002 0 0 0 0 0 0 0 0 0 0 
20 MANOJ DHUA 688903C 9/9/2005 0 0 0 0 0 0 0 0 0 0 
21 MD MOQARIM 099680D 18/9/07 0 0 0 0 0 0 0 0 0 0 
22 MITHILESH RUPAL SHARMA 289722D 21/08/2008 1 0 1 0 0 0 0 0 0 1 
23 MOHAMMED SADDAM HUSSAIN 546589C 22/11/2004 1 0 1 0 1 0 0 0 0 1 
24 NARAYAN DAS 192403C 3/9/2002 0 0 0 0 0 0 0 0 0 0 
25 NAVIN KUMAR 030815D 11/7/2007 1 0 1 0 0 0 0 0 0 1 
26 PALLAB JOSH 933376C 7/12/2006 1 1 0 0 0 1 0 0 0 1 
27 PARANTHAMAN 797561B 30/09/1999 0 0 0 0 0 0 0 0 0 0 
28 PRABU R. 992502C 16/5/2007 1 0 1 0 0 0 0 0 0 1 
29 PRADEEP KU RATREY 836850B 18/1/2000 0 0 0 0 0 0 0 0 0 0 
30 PRAVEEN KUMAR PANDE 702003C 3/11/2005 1 0 1 1 0 0 0 0 0 1 
31 RAHUL KARMAKAR 772319C 10/3/2006 1 1 0 0 0 0 1 0 0 1 
32 RAJKUMAR BEJ 143727C 10/4/2002 0 0 0 0 0 0 0 0 0 0 
33 RANJIT GHORAI 981898C 2/3/2007 0 0 0 0 0 0 0 0 0 0 
34 RAVI SHANKAR 869083C 5/9/2006 0 0 0 0 0 0 0 0 0 0 
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35 REDDAPPA 956232B 14/11/2000 0 0 0 0 0 0 0 0 0 0 
36 ROHIT KUMAR 995342C 4/4/2007 1 0 1 0 0 0 0 0 0 1 
37 SABU CHANDRA ROY 305811D 25/09/2008 1 0 1 1 0 0 0 1 0 1 
38 SAMIR NARAYAN JAMADAR 669603B 15/10/1998 0 0 0 0 0 0 0 0 0 0 
39 SANJIV KUMAR 482841C 13/07/2004 1 0 1 1 1 0 0 1 0 1 
42 SANJOY GHOSH 946311C 11/1/2007 0 0 0 0 0 0 0 0 0 0 
40 SANKIB XESS 863844C 22/8/2006 1 1 0 0 0 0 0 0 0 1 
41 SATHEESH KUMAR 833488C 13/07/2006 1 1 0 0 0 0 0 0 0 1 
43 SENTHIL 533029C 26/10/2004 1 1 0 0 0 0 0 1 0 1 
44 SHANMUGAM 841751B 5/1/2000 1 0 1 0 1 0 0 0 1 0 
45 SHASHI SHAW 845322C 3/7/2006 1 0 1 1 0 0 0 0 0 1 
46 SHEIK AFSAR 129501C 5/4/2002 1 0 1 0 1 0 0 0 0 1 
47 SHYMAL SAHA 670186B 20/10/1998 0 0 0 0 0 0 0 0 0 0 
48 SIVA KUMAR 000758C 27/3/2001 0 0 0 0 0 0 0 0 0 0 
49 SK. BILAL HOSSAN 296310D 16/09/2008 1 0 1 0 0 0 0 0 0 1 
50 SUDIP GHORAI 755910C 23/01/2006 1 1 0 0 0 0 0 0 0 1 
51 SUJOY SARKAR 245949C 15/1/2003 1 1 0 0 0 1 0 0 0 1 
52 SUMAN DAS 937451B 26/09/2000 0 0 0 0 0 0 0 0 0 0 
53 SUMAN PAL 017660D 10/5/2007 1 0 1 0 0 0 0 0 0 1 
54 SUMED KUMAR MONDAL 900189B 30/06/2000 0 0 0 0 0 0 0 0 0 0 
55 SUMIT DAS 155470C 16/5/2002 0 0 0 0 0 0 0 0 0 0 
56 SURESH M 307481C 14/8/2003 0 0 0 0 0 0 0 0 0 0 
57 TANMOY CHOWDHARY 161274C 2/5/2006 1 0 1 0 0 0 0 0 0 1 
58 UTTAM DAS 280247D 7/8/2008 1 0 1 0 1 0 0 0 1 1 
59 VENKETESAN 168407C 9/7/2002 0 0 0 0 0 0 0 0 0 0 
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1 642674B 30 25/03/2003 0 27 500 1 24 1 24 1 24 0 0 0 0 0 0 0 0 1 12 
2 064023D 1 23/08/2007 1 16 2000 1 8 1 8 1 8 1 3 1 3 0 0 0 0 1 6 
3 444588B 24 31/08/1999 0 15 600 0 0 0 0 0 0 1 2 0 0 0 0 0 0 0 0 
4 992544B 3 13/07/2001 0 13 500 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
5 991920C 36 30/03/2007 0 18 400 1 24 1 24 0 0 0 0 0 0 0 0 0 0 0 0 
6 742758B 48 18/02/2005 1 19 3000 1 24 1 24 0 0 0 0 0 0 0 0 0 0 0 0 
7 744243C 12 02/09/2006 0 15 1400 1 12 1 12 1 12 0 0 0 0 0 0 0 0 1 12 
8 201733d 6 04/07/2008 0 11 600 1 4 1 4 1 4 1 4 1 4 0 0 0 0 0 0 
9 985194B 5 01/08/2002 0 19 1200 1 5 1 5 0 0 0 0 0 0 0 0 0 0 0 0 
10 984359C 12 18/04/2007 0 26 1200 1 12 1 12 0 0 1 8 0 0 0 0 0 0 1 12 
11 960744C 12 23/01/2007 0 17 2000 1 5 1 6 1 6 0 0 1 6 0 0 0 0 0 0 
12 933376C 7 16/10/2008 0 15 1700 1 12 1 12 0 0 0 0 0 0 0 0 0 0 0 0 
13 797561B 5 14/06/2001 0 21 600 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 
14 836850B 13 22/05/2001 0 19 200 1 3 1 3 0 0 0 0 0 0 0 0 0 0 0 0 
15 944326B 16 20/10/2000 1 15 700 1 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
16 567217B 18 24/10/2000 0 20 700 1 16 1 16 0 0 0 0 0 0 0 0 0 0 0 0 
17 657486C 6 14/07/2005 0 34 300 1 24 1 24 1 24 1 24 0 0 0 0 0 0 0 0 
18 842277B 8 28/01/2000 0 11 2000 1 8 1 8 0 0 0 0 0 0 0 0 0 0 0 0 
19 492077C 3 20/08/2004 1 19 1300 1 5 1 5 0 0 0 0 0 0 0 0 0 0 0 0 
20 697573C 4 15/09/2005 0 18 400 1 12 1 12 1 12 0 0 0 0 0 0 0 0 0 0 
21 845322C 6 28/02/2007 0 17 800 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
22 129501C 13 07/04/2003 0 11 1000 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
23 822149C 2 22/06/2006 0 15 700 1 6 1 6 0 0 0 0 1 6 0 0 0 0 0 0 
24 995943C 3 04/05/2007 0 14 4600 1 1 1 1 1 1 1 2 1 1 0 0 0 0 0 0 
25 553305C 3 12/06/2005 0 17 800 1 2 1 2 0 0 0 0 0 0 0 0 0 0 0 0 
26 509205C 12 18/08/2004 0 11 1000 1 12 1 12 0 0 0 0 1 12 0 0 0 0 0 0 
27 403604C 8 01/09/2004 1 18 900 1 12 1 12 1 10 0 0 0 0 0 0 1 12 0 0 
28 821089B 6 14/01/2000 0 22 400 0 0 1 6 0 0 0 0 0 0 0 0 0 0 0 0 
29 155470C 2 13/08/2002 0 11 500 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
30 168407C 15 16/03/2004 0 18 850 0 0 1 6 1 6 0 0 1 6 0 0 0 0 0 0 
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1 1 0 0 0 2 0 2 1 0 0 0 0 
1 1 1 1 0 4 1 7 1 1 0 0 0 
0 0 1 1 0 3 0 3 1 0 0 0 1 
1 1 1 0 0 3 0 2 1 1 0 0 0 
1 1 0 0 0 1 0 2 0 0 0 0 0 
1 1 0 0 0 4 0 8 0 0 1 0 0 
1 1 0 1 0 4 1 7 0 0 1 0 0 
1 1 1 0 0 3 1 4 0 0 0 0 0 
1 1 0 0 0 4 0 5 1 1 0 0 0 
1 1 0 0 0 2 1 4 1 0 0 0 0 
1 1 0 1 0 3 1 7 0 0 0 1 0 
1 1 0 0 0 4 0 4 0 0 0 0 0 
1 1 0 0 0 2 0 2 1 1 0 0 0 
0 1 0 0 0 2 0 2 1 1 0 0 0 
1 1 0 0 0 3 0 4 1 0 0 0 0 
1 1 0 0 0 3 1 5 0 0 0 0 0 
1 1 0 0 0 3 1 4 1 0 0 0 0 
1 1 0 1 0 2 0 5 0 0 0 0 0 
1 1 1 0 1 4 1 8 0 0 0 0 0 
1 1 0 0 0 2 0 3 1 0 0 0 0 
1 1 0 0 0 3 0 4 1 0 0 0 0 
1 1 1 0 0 3 0 5 0 0 0 0 0 
1 1 0 0 1 4 1 7 0 0 0 0 0 
1 1 1 0 1 4 1 8 0 0 0 0 0 
1 1 0 0 0 1 0 1 1 1 0 0 0 
1 1 0 0 0 2 0 2 1 0 0 0 0 
1 1 0 0 0 2 1 1 0 0 0 0 0 
1 1 0 0 0 1 0 2 0 0 0 0 0 
1 1 0 0 0 1 0 1 0 0 0 0 0 
1 1 0 1 0 1 0 2 0 1 0 0 0 
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NO 
HOSPITAL 
NO NC SPF NPX MS ES SS TPF PP BAS INT INF IOF SOF OA PPS FO FR EXT CS
1 642674B 0 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 
2 064023D 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 
3 444588B 0 0 0 0 0 0 1 1 1 0 1 1 0 0 0 0 0 0 0 
4 992544B 1 1 1 0 1 0 1 0 1 0 1 1 0 0 0 0 0 0 0 
5 991920C 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
6 742758B 1 1 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 
7 744243C 1 1 1 0 1 1 1 1 1 1 0 0 0 0 1 0 1 1 1 
8 201733d 1 1 1 0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 0 
9 985194B 1 1 1 0 1 1 1 1 1 0 1 1 0 0 0 0 1 1 1 
10 984359C 1 1 1 0 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 
11 960744C 1 1 1 0 1 1 1 1 1 1 1 0 0 0 1 0 0 0 0 
12 933376C 1 1 1 1 0 1 1 0 0 0 1 1 0 0 0 0 0 1 1 
13 797561B 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
14 836850B 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
15 944326B 1 1 1 0 0 1 0 0 1 1 1 0 0 0 1 0 0 0 0 
16 567217B 1 1 1 0 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 
17 657486C 1 1 1 0 1 1 1 0 1 0 1 0 0 0 0 0 0 0 0 
18 842277B 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
19 492077C 1 1 1 1 1 1 1 0 1 0 1 1 0 1 0 0 1 1 1 
20 697573C 1 1 1 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 
21 845322C 1 1 1 0 0 1 1 0 1 0 1 1 0 0 0 0 0 0 0 
22 129501C 1 1 1 0 0 1 1 1 1 1 1 0 0 0 1 0 0 0 0 
23 822149C 1 1 1 0 0 1 1 0 1 0 1 1 1 1 0 0 1 1 1 
24 995943C 1 1 1 1 1 1 1 0 1 0 1 1 1 1 0 0 1 1 1 
25 553305C 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
26 509205C 1 1 1 0 0 1 0 1 1 1 0 0 0 0 0 0 0 0 0 
27 403604C 1 1 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 
28 821089B 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
29 155470C 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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30 168407C 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
NO NAME HOSPITAL 
NO 
DOS embolization I/L IMA B/L IMA APA OPHTH VIDIAN MENINGEAL cavernous PVA gelform
1 BENIMADHEB 642674B 25/03/2003 0 0 0 0 0 0 0 0 0 0
2 BHOLA SANKAR YADAV 064023D 23/08/2007 1 1 0 1 0 0 0 0 0 1
3 BISWAJIT GHUGHU 444588B 31/08/1999 0 0 0 0 0 0 0 0 0 0
4 DIPANKAR MAJUMDAR 992544B 13/07/2001 0 0 0 0 0 0 0 0 0 0
5 DIPU KUNDU 991920C 30/03/2007 0 0 0 0 0 0 0 0 0 0
6 GOUTAM KUMAR MAITY 742758B 18/02/2005 0 0 0 0 0 0 0 0 0 0
7 HARUNAR RASHID 744243C 02/09/2006 1 0 1 1 0 0 0 0 0 1
8 KANHA GOWSWAMI 201733d 04/07/2008 1 1 0 0 0 0 0 0 0 1
9 KIRAN BAG DAS 985194B 01/08/2002 0 0 0 0 0 0 0 0 0 0
10 MOGIDUL ISLAM MOOLLA 984359C 18/04/2007 1 0 1 0 0 0 0 0 0 1
11 MONORANJAN BISWAS 960744C 23/01/2007 1 0 1 0 0 0 0 0 0 1
12 PALLAB JOSH 933376C 16/10/2008 0 0 0 0 0 0 0 0 0 0
13 PARANTHAMAN 797561B 14/06/2001 0 0 0 0 0 0 0 0 0 0
14 PRADEEP KU RATREY 836850B 22/05/2001 0 0 0 0 0 0 0 0 0 0
15 PRAOSENJIT DEY 944326B 20/10/2000 0 0 0 0 0 0 0 0 0 0
16 PRASAD 567217B 24/10/2000 1 0 1 0 0 0 0 0 0 1
17 RAMESHWAR RAM 657486C 14/07/2005 1 0 1 0 0 0 0 0 0 1
18 SANTOSH DEY 842277B 28/01/2000 0 0 0 0 0 0 0 0 0 0
19 SANTOSH PANDIT 492077C 20/08/2004 1 1 0 0 0 0 1 0 0 1
20 SANTU NONGRUM 697573C 15/09/2005 0 0 0 0 0 0 0 0 0 0
21 SHASHI SHAW 845322C 28/02/2007 0 0 0 0 0 0 0 0 0 0
22 SHEIK AFSAR 129501C 07/04/2003 0 0 0 0 0 0 0 0 0 0
23 SIMON BABU 822149C 22/06/2006 1 1 0 0 0 0 0 0 1 1
24 SK ASMOT ALI 995943C 04/05/2007 1 0 1 0 0 0 0 0 0 1
25 SOURAV MODAK 553305C 12/06/2005 0 0 0 0 0 0 0 0 0 0
26 SUDIPTA MUKHERJEE 509205C 18/08/2004 0 0 0 0 0 0 0 0 0 0
27 SUDUN KU SHIL 403604C 01/09/2004 1 0 1 0 0 0 0 0 0 1
28 SUJOY KUNDU 821089B 14/01/2000 0 0 0 0 0 0 0 0 0 0
29 SUMIT DAS 155470C 13/08/2002 0 0 0 0 0 0 0 0 0 0
30 VENKETESAN 168407C 16/03/2004 0 0 0 0 0 0 0 0 0 0
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CLINICAL SIGNS OF JNA 
 
 
Fig.1. Mass in nasal cavity 
 
 
Fig.2. Cheek swelling 
 
 
Fig.3. Soft palate bulge 
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STAGE I TUMOUR 
 
                  
 
 
Fig.4a. Coronal CT scan shows a mass filling left nasal cavity (black arrow).b. Axial CT 
scan filling left nasopharynx (white arrow). 
 
 
 
 
 
 
 
 
STAGE II TUMOUR 
 
                  
   
 
Fig.5a. Coronal CT scan shows a mass filling right nasal cavity and sphenoid sinus 
(black arrow).b. Axial CT scan filling right sphenoid sinus(white arrow). 
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STAGE III TUMOUR 
 
                   
 
 
Fig.6a. Coronal CT scan shows a mass filling left nasal cavity, nasopharynx, 
pterygopalatine fossa and infratemporal fossa (black arrow).b. Axial CT scan filling left 
infratemporal fossa(white arrow). 
 
 
 
 
 
 
 
 
STAGE IV TUMOUR 
 
                     
 
 
Fig.7a. Coronal CT scan shows a mass filling left nasopharynx, sphenoid sinus, right 
cavernous sinus(black arrow).b. Axial CT scan filling left cavernous sinus(white arrow). 
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ANGIOGRAM 
 
 
   
Fig.8. Angiogram shows abnormal tumor blush in the region supplied by left internal 
maxillary artery. 
 
 
 
 
POST EMBOLIZATION ANGIOGRAM 
 
 
 
 
Fig.9. Post embolization check angiogram showed good occlusion of embolized vessel 
and absence of tumor blush. 
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SURGICAL APPROACHES 
 
           
    
Fig.10. Transpalatal approach                             Fig.11. Midfacial Degloving approach 
 
 
 
 
 
 
 
Fig.12. Extended osteoplastic maxillotomy approach 
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Fig.13. Lateral rhinotomy approach 
 
 
 
 
 
Fig.14. Infratemporal fossa approach 
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SURGICAL SPECIMEN OF JNA 
 
 
 
Fig.15.Typical pink, smooth surfaced, lobulated mass 
 
 
 
POST OPERATIVE  
 
                       
 
Fig.16. Post operative lateral rhinotomy:                        Fig.17. Palatal fistula 
            Acceptable Cosmesis 
